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The main aim of this thesis was to gain knowledge about the oncological safety of nipple-
sparing mastectomy (NSM) with immediate implant-based reconstruction and delayed Deep 
Inferior Epigastric Perforator (DIEP) flap breast reconstruction. In this context, we also 
considered the impact of discrepancies in socioeconomic status (SES) and comorbidity. 
Finally, we investigated the effects of radiotherapy (RT) on implant-based immediate breast 
reconstruction (IBR) measuring failure rates, number of unplanned reoperations and patient-
reported outcomes (PROs). 
In study I, we studied the local recurrence rates as well as disease-free, overall and breast 
cancer-specific survival (BCSS) after NSM and IBR compared with a matched control group 
of patients undergoing conventional mastectomy. Matching variables were tumour stage, age, 
and year of mastectomy. A total of 69 NSM cases and 206 conventional mastectomies operated 
between 2000 and 2012 were included. While no local recurrence occurred in the study group, 
seven were observed in the control group (P=0.197). Survival rates did not differ significantly 
between groups. 
In study II, we aimed to estimate the risk of breast cancer recurrence after DIEP flap 
reconstruction compared with patients treated with mastectomy without any delayed 
reconstruction. A total of 254 DIEP cases operated between 1999 and 2013 and 729 control 
cases were included. Matching variables were age, tumour stage, neoadjuvant therapy, and year 
of DIEP flap reconstruction. The primary endpoint, 5-year BCSS, was significantly higher in 
the DIEP group, which did not persist after adjustment for tumour and patient characteristics 
and treatment. Overall survival (OS) remained significantly lower in the control group despite 
adjustment. We therefore aimed to address the observed survival differences by further 
adjusting for SES) and comorbidity in study III. Data for the estimation of the Charlson 
Comorbidity Index and SES were obtained from Swedish national registers. In the DIEP group, 
it was more common to continue education after primary school, to have a higher income, and 
to be in a partnership. Women in the DIEP group were also significantly healthier than women 
in the control group. After adjustment for SES and comorbidity, however, OS was still 
significantly better in the DIEP group than the control group, which is potentially due to 
unaccounted confounders such as body mass index (BMI), smoking and selection bias inherent 
to the reconstructive decision-making process. 
 
In study IV we re-evaluated a previously reported large homogenous IBR cohort with regards 
to surgical results and PROs. All women undergoing a therapeutic mastectomy with implant-
based IBR at Stockholm’s main four hospitals between 2007 and 2011 were included (N=754 
IBRs). Of those, 386 had not been irradiated, 64 were irradiated prior to IBR, and 304 after 
IBR.  The primary endpoint was IBR failure, defined as implant removal due to any cause, with 
or without a conversion to an autologous reconstruction.  BREAST-Q questionnaires were sent 
out to all patients alive with no record of implant removal. Between-group comparisons and 
longitudinal within-groups differences were assessed. IBR failure occurred in 128 cases (17%) 
with the higher proportion in the postoperative and prior RT groups, 24.3% and 31.3% 
respectively, (P<0.001). Independent risk factors for IBR failure were irradiation, age > 50 at 
time of IBR, BMI ≥ 25, and postoperative surgical complication. With a response rate of 72.2%, 
women with prior RT scored significantly lower than those without RT on most subscales, 
while women with postoperative RT reported significantly lower scores on physical well-being 
only. Among responders, psychosocial well-being had increased over the past eight years in 
the postoperative RT group, and satisfaction with breasts and with overall outcome had 
significantly decreased in the no RT group. Of note, women with implant failure after 
irradiation were not included in PROs analysis since the specific questions are not applicable 
to someone who has either had her implant removed or converted to an autologous 
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1 BACKGROUND  
Breast cancer is the most frequently diagnosed cancer in women of all regions of the world, 
representing 22% (1.38 million) of all cancer cases worldwide1,2. It accounts for approximately 
14% (523 000 cases were diagnosed in 2018) of all malignancies in Europe, making it one of 
the leading causes of cancer-related death, accounting for 22% (138 000) of cancer deaths in 
European women in 20181. The incidence in developed countries is 80 cases per 100 000 
women but <40 cases per 100 000 women in developing countries where the incidence is rising, 
possibly due to improving diagnostics and a more “western-like” lifestyle. In Sweden, about 
8400 women were diagnosed with breast cancer in 2012, 8093 in 2017, 7952 in 2018, and 8288 
in 20193. Figure 1a-b presents the incidence and mortality in Sweden since the 1960s, with an 
age-standardized incidence rate now reaching 84.7 per 100 000 female individuals4. Due to 
screening, early-stage presentation is most common; in the United States (U.S) for example, 
about 61% of women present with localized breast cancer and only 32% have regional lymph 
node involvement5. Survival rates have been increasing in western countries during the past 
decades, commonly attributed to mammography screening and advances in oncological 
treatment, along with increasing breast cancer awareness and improving general healthcare6.  
 
 
Figure 1a. (left) presenting the age-standardized breast cancer incidence in Sweden per 100 000 
women (red curve) and breast cancer mortality (green curve) 1b. (right) Breast cancer mortality per 





Breast cancer is diagnosed by triple assessment including clinical examination, radiological 
assessment with mammography and/or ultrasound, and pathological confirmation by either 
fine-needle aspiration cytology or core needle biopsy. The triple assessment has a sensitivity 
of almost 100%7 and if any doubts remain thereafter, magnetic resonance imaging (MRI) or a 
diagnostic surgical biopsy may be helpful8. Mammography screening was first introduced in 
Sweden in 1986 and was thereafter implemented nationally. Today, all women between the 
age of 40 and 74 years are invited to mammography screening with the interval of 24 months, 
according to guidelines by The Swedish National Board of Health and Welfare9.   
The management of breast cancer requires a multidisciplinary approach in both diagnostics and 
treatment. According to Swedish guidelines, each patient should be discussed at pre- and 
postoperative multidisciplinary meetings as established more than 25 years ago, bringing 
together a breast surgeon, breast radiologist, breast oncologist, pathologist, and a breast nurse. 
Based on the team discussion of the results including tumour and nodal stage, tumour type, any 
genetic predisposition, tumour biology, and other patient characteristics such as age and 
comorbidity, a treatment recommendation is given10. 
 
1.1 TUMOUR CLASSIFICATION, PROGNOSTIC AND TREATMENT-
PREDICTIVE FACTORS 
1.1.1 TNM classification 
The TNM staging system is developed by the American Joint Committee on Cancer (AJCC)11. 
Its classification is based on tumour size (T), regional lymph node metastasis (N) and distant 
metastasis (M), and represents the single most important prognostic factor in breast cancer12. 
The TNM system classifies breast cancer into four stages with close associations to survival.  
The 5-year overall survival (OS) in stage 0-I disease is nearly 100%, approximately 80% in 
stage II, 60% in stadium III, but barely 20% in stage IV8. The overall 5-year survival rate in 
Sweden has increased over the past decade, now approaching 83%3. 
TNM stage is defined at different time points during the cancer treatment: The clinical or 
radiological assessment before the initiation of tumour treatment defines clinical stage, whereas 
pathological stage is based on the histopathological examination of surgically removed tissue. 
If the latter is undertaken after preoperative systemic treatment, the TNM classification is 




1.1.2 Histological Grade 
Histological grade is a strong prognostic factor, first described in 195713 and later modified by 
Elston and Ellis in 199114. The overall grade is based on three morphological features of the 
cancer cells including tubular formation, nuclear atypia and mitotic count, each of which 
creates a score that is added together to an overall grade of I-III, today referred to as the 
Nottingham histological grade (NHG).  
 
1.1.3 Biomarkers 
Routinely assessed biomarkers include Oestrogen receptor (ER), Progesterone receptor (PgR), 
human epidermal growth factor receptor 2 (HER2), and the proliferation marker Ki6715. These 
biomarkers provide both prognostic and treatment-predictive information. ER was first 
identified in the 1970s through the association with a beneficial tumour response after 
endocrine ablation16. The receptor is expressed in up to 80-85% of invasive breast tumours, 
offering a target for endocrine therapy.  
PgR expression is dependent on oestrogen signalling via ER17, and its prognostic value has 
been disputed18,19. Still, tumours expressing PgR are associated with better outcomes than PgR-
negative tumours20-22. The threshold for ER and PgR positivity, earlier set to 10%, was updated 
in recommendations by the American Society of Clinical Oncology (ASCO) and the College 
of American Pathologists (CAP) in 2010, and tumours expressing ER or PgR in at least 1% of 
the tumour nuclei are since considered positive23,24. A follow-up study including 9639 cases, 
however, showed no strong additional benefit of endocrine therapy in tumours with 1-9% of 
ER positivity25,26 and therefore, a threshold of 10% is incorporated in the Swedish guidelines8. 
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor located on the 
cell membrane, overexpressed in about 10-15% of all breast cancers24,27,28. It is involved in a 
signalling network controlling cellular proliferation, associated with the capacity of metastatic 
dissemination leading to more aggressive tumour traits, and is correlated to worse overall 
survival29,30. HER2 is primarily assessed by immunohistochemistry (IHC) and subsequently 
completed by situ hybridization if amplification is suspected8.  
Ki67 is a nuclear protein expressed only in proliferating cells, reflecting the tumour 
proliferation rate, and reported as a value between 0 and 100% representing the proportion of 
proliferating tumour cells. There are still debates on a standardized cut-off value to distinguish 
between high, intermediate and low proliferative tumours24,25,31,32. The proliferation index is 
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determined through Ki67 or MIB-1, which are monoclonal antibodies directed against the Ki67 
protein.  
A prognostic factor is defined as a factor that provides information about recurrence or survival 
independently of treatment effects. Information about such factors can be useful in the selection 
of patients for a certain treatment, but does not predict the response to the treatment33. A 
predictive factor, on the contrary, provides information on the effect of a therapeutic 
intervention in a patient, and thus an estimate for the response to treatment34. Predictive 
biomarkers can be specifically targeted by therapy33 and guide the selection of treatment 
strategies, e.g. ER positivity for endocrine therapy and HER2 positivity for targeted 
immunotherapy. Thus, hormone receptor status, HER2 status and histological grade act as 
determinants for the type of adjuvant systemic therapy recommended34. A high proliferation 
rate, although an independent prognostic factor, is not predictive of benefit from chemotherapy 
or endocrine treatment35. 
 
1.1.4 Molecular subtypes 
Breast cancer comprises a heterogeneous group of tumours with distinct molecular features. 
The classification of intrinsic molecular subtypes was first described by Perou and Sørlie et al 
in 199936,37: Four subtypes of different gene expression patterns were identified and termed 
luminal, HER2-enriched, basal-like, and normal-breast like. Further luminal subtyping 
followed with the distinction between luminal A and luminal B38. Molecular subtypes have 
been translated into corresponding surrogate subtypes as determined by the expression of 
hormone receptors, HER2 and proliferation markers39,40. Today, surrogate intrinsic subtypes 
are five: luminal A (ER and PgR positive, HER2 negative, low proliferative activity), luminal 
B (ER and PgR positive, high proliferative activity, HER2 negative), HER2-positive luminal 
(ER and PgR positive, HER2 positive), HER2-positive non-luminal (ER and PgR negative, 
HER2 positive), and triple-negative breast cancer (TNBC) (ER and PgR negative, HER2 








The clinical importance of breast cancer subtypes has been widely reported11,43,44 and 
incorporated into the St. Gallen clinical guidelines in 201125,41. This subtype classification is 






Figure 2. Flow chart presenting the surrogate intrinsic subtype classification according to the Swedish 
guidelines. ER-positivity defined as ER ≥10% whereas laboratory-specific cut-offs are used for Ki67 





1.2 BREAST CANCER TREATMENT  
Breast cancer treatment is multimodal with both locoregional and systemic treatment 
approaches. Systemic therapy is given with the aim to eliminate residual locoregional as well 
as systemic micrometastatic disease, thereby lowering the risk of breast cancer recurrence45. 
Neoadjuvant, i.e. preoperative, systemic treatment can be chosen with the aim to down-stage 
the primary tumour and allow for less extensive surgery in the breast and axilla. Locoregional 
treatment modalities are surgery and radiotherapy: while surgery focuses on eliminating the 
macroscopic tumour burden, radiotherapy eradicates microscopic residual disease. 
 
1.2.1 Surgery 
The modern history of breast cancer treatment dates back to 1882, when William Halsted 
performed the first radical mastectomy removing the whole breast together with the underlying 
pectoralis major and minor muscles and the ipsilateral axillary lymph nodes46,47. The procedure 
was associated with disfigurement and severe morbidity including persistent pain, sensory loss, 
severe lymphedema, and restricted shoulder mobility47. Since then, major improvements have 
evolved, resulting in more conservative approaches in both breast and axillary surgery. In the 
breast, the most common surgical alternatives are breast-conserving surgery (BCS) and 
mastectomy (today leaving the pectoral muscles untouched). In the axilla, more precise staging 
methods such as the sentinel lymph node biopsy have in many situations replaced full axillary 
lymph node dissection (previously always part of a radical mastectomy), and thus spare patients 
the heavy comorbidity seen with previous approaches. Surgical tumour resection remains the 
primary component of breast cancer treatment and may in many cases be curative without 
further therapy. 
BCS is the surgical removal of the tumour with an appropriate margin of healthy surrounding 
tissue and is, in combination with radiotherapy, the golden standard in women with early-stage 
breast cancer48. About 68% of all breast cancer patients in Sweden receive BCS10. In tumours 
up to three cm, the proportion is as high as 83%8. However, mastectomy may be necessary due 
to large tumour size, multifocality, centrally situated tumours, patient preference, or 
inflammatory breast cancer10. It implies the removal of the entire breast gland, with or without 






Although breast cancer surgery removes macroscopic disease, undiagnosed microscopic 
tumour foci may be left behind in residual breast tissue, lymph nodes or lymph tracts resulting  
in locoregional recurrence (LRR) or distant metastasis if left untreated49,50. Postoperative 
radiotherapy (RT) is recommended in order to eradicate microscopic residual disease, thereby 
reducing the risk of LRR and improving breast cancer-specific survival (BCSS) both in the 
setting of BCS50 and mastectomy in node-positive disease49,51,52. Local RT targets the 
remaining breast tissue, overlying skin and underlying chest wall after BCS (whole breast 
irradiation, WBI) or the skin and chest wall after mastectomy (post-mastectomy radiotherapy, 
PMRT), while locoregional RT additionally targets draining lymphatics in the axilla and supra- 
and infraclavicular fields, and the internal mammary chain in selected cases.   
For indication and target delineation of postoperative RT, information on axillary lymph node 
status, tumour size and surgical method is crucial8,10. National guidelines today recommend RT 
delivered as two tangential fields in 15 fractions, resulting in a total dose of 40 Gray. An 
additional boost dose of 10-16 Gray is given to patients younger than 50 years10.  
According to recommendations by the European Society of Breast Cancer Specialists 
(EUSOMA), RT should be considered if the risk of local recurrence (LR) following breast 
surgery is estimated to be at least 20% at 10 years after diagnosis52. This has been incorporated 
into the Swedish and European guidelines, recommending WBI to patients undergoing BCS8,53.  
WBI can be omitted in cases of pure in situ disease of NHG 1-2 if the total extent does not 
exceed 15 mm and if clear margins are achieved (>2 mm)8. Investigations by the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) suggest a reduced 10-year recurrence risk 
from 35% to 19.3% (CI 13.7–17.7, P<0.00001) in those receiving WBI after BCS50. 
Furthermore, breast cancer mortality 15 years after diagnosis is reduced from 25.2% to 21.4% 
(P=0.00005)50.  
In node-positive breast cancer, RT to regional lymph nodes is recommended in Sweden 
independent of the type of breast surgery performed, and is always combined with local RT, 
i.e.WBI after BCS or PMRT after mastectomy: After mastectomy, the risk of breast cancer 
recurrence as well as breast cancer mortality in women with node-positive disease is reduced 
if RT is given49,51,54. In a meta-analysis by the EBCTCG, including 13132 patients, locoregional 
RT reduced breast cancer recurrence (RR=0.86, 95% CI 0.79–0.94, P=0.0006), breast cancer 
mortality (RR=0.81, 0.74–0.90, p<0.0001) and overall mortality (RR=0.86, 0.80–0.93, 
P=0.0002) in all nodal stages54. If only axillary micrometastases are present, however, and in 
patients with only a single macrometastasis and favourable tumour biology (i.e. luminal A), 
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local RT after BCS (WBI) is deemed sufficient, and no RT is recommended after mastectomy8. 
PMRT can be further omitted in pure in situ tumours of limited extent and in case of lymph 
node negativity in T1-T2 stage tumours excised with clear margins10. PMRT is, however, 
recommended if the tumour size exceeds 5 cm regardless of nodal stage or if extensive 
multifocality is present8.  
In a meta-analysis including 8135 women, locoregional RT reduced the locoregional 
(P<0.00001) and overall recurrence risk (P=0.0003) and breast cancer mortality (P=0.04) in 
women with four or more positive lymph nodes undergoing mastectomy, independent of 
systemic therapy51. In another systematic review and meta-analysis, RT was shown to 
significantly reduce the risk of LRR even in case of one to three positive lymph nodes55. A 
beneficial but limited effect was also seen on OS. In many countries, however, the role of 
locoregional RT in patients with early-stage T1–2 disease with limited nodal metastasis, i.e. 
one to three positive lymph nodes, remains a subject of debate56. In these cases, RT could be 
omitted in patients lacking specific risk factors for LRR, i.e. patients over the age of 40 with 
clinical stage I-II, unifocal tumours of luminal A subtype with clear surgical margins, and 
additionally in those achieving pathological complete remission in the breast and lymph nodes 




1.2.3 Chemotherapy  
Chemotherapy has been part of breast cancer treatment since the 1960s59. In a meta-analysis 
by the EBCTCG including data on 100 000 women, a combination of 5-flurouracil, epirubicin 
and cyclophosphamide resulted in a 16% reduction of recurrence and 21% reduction of 
mortality compared with no cytotoxic treatment60. More recent regimens include taxanes either 
following anthracycline-based treatment or alone61, routinely used for high-risk tumours such 
as triple-negative or HER2-positive breast cancer34,53. 
Adjuvant chemotherapy prolongs recurrence-free and breast cancer-specific survival22,61. It is 
not clear, however, whether it completely eradicates or only reduces the size of occult distant 
tumour foci34. Adjuvant chemotherapy has been suggested to benefit almost all groups of breast 
cancer patients, although not necessarily to the same degree22. Chemotherapy is, however, 
associated with significant adverse side effects, some of which are temporary and relatively 
easily managed while others are more serious and long-lasting, including severe toxicities that 
may lead to treatment-associated mortality62. Some suggest that patients with an estimated 
recurrence risk higher than 10% over the course of 10 years should be considered potential 
candidates for chemotherapy63. According to Swedish guidelines, chemotherapy is 
recommended on the base of the combination of a number of risk factors such as high grade 
and/or high proliferation, TNBC and HER2-positive subtypes, lymph node positivity, and 
young age8.  
Neoadjuvant chemotherapy (NACT) was originally only indicated in locally advanced or 
inflammatory breast cancer. Today, however, it is used in an increasing number of patients 
with aggressive tumour biology. NACT helps to monitor treatment response, thus allowing 
treatment adaptation if response is lacking, and increases the likelihood for breast-conserving 
surgery10,34,64-66. The proportion of tumours responding to neoadjuvant chemotherapy varies 
dependent on tumour subtype65,67-71, and pathological complete response (pCR) positively 
correlates with better breast cancer-specific survival72.   
In Sweden, 9.0% of breast cancer patients were treated with NACT in 20193, which is low in 
comparison to other countries. A survey addressing international multidisciplinary teams 
showed that the proportion of all breast cancer patients receiving NACT in Australia, Germany, 




1.2.4 Endocrine therapy  
Approximately 80-85% of breast cancers are oestrogen receptor positive (ER+), in which case 
adjuvant endocrine therapy is recommended8,53,74. Endocrine treatment reduces endogen 
hormone activity either by blocking hormone receptors through competitive linkage or by 
inhibition of the precursor conversion to bioactive stages: Selective oestrogen receptor 
modulators (so-called SERMs) such as Tamoxifen have anti-estrogenic properties by 
competing with oestrogen in target tissues75,76. SERMs are most often used in premenopausal 
and low-risk postmenopausal women. Aromatase inhibitors (AI) such as anastrozole are 
inhibitors of the aromatase enzyme, resulting in a diminished oestrogen production, most often 
used in medium to high-risk postmenopausal women77.   
An absolute reduction of breast cancer mortality by 9.2% during the first 15 years post 
treatment (relative risk: 0.71 during years 0-4, 0.66 during years 5-9 and 0.68 during years 10-
14) has been shown for ER+ patients after five years of Tamoxifen treatment18. In another 
meta-analysis by the EBCTCG on 32 000 ER-positive tumours in postmenopausal women 
comparing the effects of AI and Tamoxifen, the relative risk of recurrence was lowered by 30% 
for those treated with AI. A decrease of breast cancer mortality (RR 0.86, P<0.001) was in 
favour of AI78. Importantly, however, EBCTCG reported late breast cancer recurrences 
throughout a follow-up of 5-20 years after five years of adjuvant endocrine therapy in 2017; 
risk factors associated with late distant recurrences were large tumour size and advanced 
axillary status. Prolonged endocrine therapy lasting for 10-15 years is therefore recommended 
in selected patients79. 
The addition of bisphosphonates to endocrine treatment inhibits osteoclast-mediated bone 
resorption and thereby reduces the risk of distant metastases80. A significantly lower 10-year 
risk for distant metastasis was seen in patients treated with adjuvant bisphosphonates versus 
controls (20.4% vs 21.8%, P=0.03)81, and the 10-year risk of bone metastasis was 7.8% versus 
9.0% (P=0.004) leading to a significantly reduced breast cancer mortality in the treatment 
group. Bisphosphonates may also improve health-related quality of life (HRQoL) in cancer 




1.2.5 Anti-HER2 targeted therapy  
Before the humanized anti-HER2 targeted monoclonal antibody trastuzumab (Herceptin®) 
was introduced, HER2-positive tumours carried a dismal prognosis34. After several large 
randomized controlled trials (RCT), trastuzumab was added to the standard chemotherapy 
regimen, improving the prognosis for patients with HER2-positive tumours considerably83,84: 
A meta-analysis concluded a 40% reduction in the proportional risk of recurrence along with 
34% relative improvement in overall survival (HR 0.66: 95%CI 0.57-0.77)85. Today, patients 
with HER2-positive tumours larger than 5 mm are offered anti-HER2 treatment regardless of 
age or menopausal status8,53,86. In the neoadjuvant setting, a combination of the HER2 
antibodies trastuzumab and pertuzumab (“double blockade”) is given, resulting in significantly 










1.3 BREAST RECONSTRUCTION  
Around 36% of all breast cancer patients in the U.S underwent mastectomy year 201191 and 
the corresponding figure in Sweden was 32% in 20198. In conventional mastectomy, the breast 
glandular tissue is removed together with the overlying skin and the nipple-areola complex 
(NAC). The procedure is associated with negative psychological effects resulting in reduced 
self-esteem, changed body image and impaired sexual function92. Further development of 
conventional mastectomy techniques led to skin preservation, which results in better aesthetic 
outcomes and allows an improved breast shape in the reconstructed breast93: In skin-sparing 
mastectomy (SSM), at least parts of the native skin envelope are preserved for an immediate 
breast reconstruction (IBR), and in nipple-sparing mastectomy (NSM), also the nipple-areola 
complex (NAC) is preserved.  
 
Following mastectomy, breast reconstruction can be performed as an immediate or delayed 
procedure, each of which can be done using a breast implant or autologous tissue to recreate 
the breast mound, or a combination of both. The goal of post-mastectomy breast reconstruction 
is to restore the appearance of the breast and thereby mitigate the psychological impact of 
cancer surgery94-98. The choice of reconstruction method is multifactorial and based on tumour 
characteristics, the reconstructive setting (immediate or delayed), body habitus, any pre-
existing comorbidity, patient preference and patient-received information. All patients planned 
for mastectomy are recommended to receive preoperative information about available 
reconstruction methods, and those wishing IBR without any significant contraindication should 
be offered one99. 
The rates of IBR have been steadily increasing over the past decade100-103. Implant-based 
reconstructions account for almost 65% of all breast reconstructions in the U.S. and are 
considered safe, cost-effective and reliable104-107. Since implant-based IBR is the least 
demanding reconstructive method, it can be performed despite limited comorbid conditions108. 
Contraindications for IBR include inflammatory cancer, tumour-growth into the skin or the 
chest wall, simultaneous distant metastasis, smoking and obesity. Although no clear cut-off has 
been explicitly set, a body mass index (BMI) above 30 is regarded as contraindication for breast 




1.3.1 Immediate breast reconstruction 
The first silicone breast implant was introduced in the 1960s and evolved into a tissue expander 
which was used from the 1990s onwards109,110. Since then, implants have developed to vary in 
material (hydrogel-filled or different cohesivity versus saline-filled expanders/implants), 
surface texture (smooth versus textured silicone implants), design (variable volume or fixed 
volume), and shape (anatomical versus round)111,112. 
In Sweden, implant-based reconstruction is the predominant method in the setting of IBR, 
performed in about 16% of women undergoing mastectomy nationwide, but in 32% in the 
Stockholm region in year 20193. The proportion of breast cancer patients undergoing implant-
based IBR in Sweden, even though still low in an international comparison, has steadily been 
increasing since 20003. Autologous reconstruction methods are more commonly chosen in a 
delayed setting in Sweden, but commonly performed as an immediate breast reconstruction in 
other countries113-116.  
Implant-based reconstruction can either be performed with the implants placed in a subpectoral 
pocket or in the prepectoral space, with or without the additional use of acellular dermal matrix 
or synthetic mesh, and further performed as a one-stage direct-to-implant reconstruction or in 
a two-stage setting, first placing an expander implant which is later replaced by a definitive 
implant. In one-stage reconstruction, permanent implants are used in order to reconstruct a 
definitive breast mound at the time of mastectomy, without the need for tissue expansion and 
tissue expander to implant exchange104. Some state that women with small-to-medium and non-
ptotic breasts are best suited for the procedure117. No significant delay in the time to adjuvant 










1.3.2 Nipple-sparing mastectomy 
Immediate breast reconstruction implies that larger parts of the native skin envelope need to be 
preserved, necessitating specific types of mastectomy such as skin-sparing mastectomy (SSM) 
or nipple-sparing mastectomy (NSM) in order to achieve a superior cosmetic outcome48. The 
preservation of the nipple-areola complex (NAC) in NSM results in higher psychological 




Figure 3. Non-irradiated patient 
with bilateral nipple-sparing 
therapeutic mastectomy and implant-
based immediate breast 
reconstruction. The left breast holds 
a permanent, partly saline-filled 
expander, while the right breast 
holds a permanent implant after 
expander exchange. Photo: Jana de 
Boniface. 
 
Some doubts have been raised about the oncological safety of NSM since breast tissue such as 
terminal ducts could be left behind in the preserved NAC and potentially lead to 
recurrence122,123. Terminal duct lobular units (TDLU) constitute the basic functional and 
histopathological unit of the breast. TDLU consist of intra- and extralobular terminal ducts with 
an associated lobe and range in size from 1 to 4 mm. The units connect to ducts of each breast 
lobe, draining through collecting ducts terminating in the nipple. Although residual breast 
tissue can be found throughout the whole area of the chest wall, breast tissue could more often 
be left behind on the skin flaps after conventional mastectomy, at the periphery of the breast 
mound if more technically challenging accesses are used, or underneath the NAC124. Some 
researchers show that up to 76.2% of conventional mastectomy specimens contain breast tissue 
at the resection margins across the superficial dissection surface124-126.    
NAC involvement, i.e. occult tumour involvement of the nipple-areola complex, may lead to 
incomplete excision of the tumour. The incidence of NAC involvement ranges from 0% to 
58%, most probably dependent on criteria for patient selection and pathologic assessment127-
131. Several studies have reported an increased risk of NAC involvement in large tumours in 
the vicinity of the NAC, in centrally located tumours, high-grade tumours, tumours with 
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positive axillary lymph nodes, an extensive in situ component, and lymphovascular invasion132-
135. Another factor increasing the risk of NAC involvement is a short tumour-nipple distance 
(TND)136,137. Consequently, one of the established criteria for attempting NSM is a TND of at 
least 1-2 cm as judged by clinical examination and imagining. The only absolute 
contraindication for NSM remains clinical NAC involvement, while relative contraindications 
include a short TND and locally advanced disease. In order to confirm that the NAC can be left 
in place in NSM, a retroareolar biopsy should always be examined to assure that no NAC 
involvement is present. 
The risk of local recurrence following NSM or SSM in the context of IBR has been widely 
investigated and a selection of these studies is presented in Table 193,134,136,138-153. 
     
 * Mean follow-up time 
Table 1. A selection of studies reporting on the local recurrence following nipple-sparing or skin-
sparing mastectomy. 
 
A systematic review of 13 studies found 144 recurrences in 2015 patients undergoing NSM. 
Conclusions were, however, hard to draw due to lack of adjusting for potential confounding 
factors such as adjuvant radiotherapy, age, surgical techniques, stage of disease, ductal 
carcinoma in situ or invasive breast cancer, and chemotherapy in many of the studies154. 
Another meta-analysis and systematic review of 20 studies presented factors associated with 
OS, disease-free survival (DFS) and local recurrence (LR), supporting the safe use of NSM155. 













Gerber (2009) 61 0-III 11.7 1.6 101* 
Petit  (2008) 579 0-I 0.9 0 19 
Benediktsson (2008) 216 0-III 24.0 - 156 
Paepke (2009) 109 0-III 0.9 0 34 
Coopey (2013) 315 0-III 2.6 0 22* 
Smith  (2017)  311 0-III 2.2 0 51 
Poruk (2015) 130 0-IV 0.8 - 25.8 
Frey (2016) 118 0-III 0.8 0 30.7 
Margenthaler (2020) 399 0-III 1.0 0 Not reported 
Adam (2014) 69 I-IV 0  0 36 
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In a recent systematic review comparing NSM to SSM, no statistically significant difference in 
5-year DFS and mortality was shown, and LR rates were similar (3.9 vs 3.3 %, P=0.45)156.   
Based on the data presented above, NSM is considered to be an oncologically safe choice in 
carefully selected women53,139,149,155,156. 
 
1.3.3 The effects of radiotherapy on implant-based immediate breast reconstruction  
The proportion of IBR patients receiving post-mastectomy radiotherapy (PMRT) has increased 
over time91,157. Analyses of trends for studies reported to the U.S. National Cancer Database 
showed an increase in the proportion of women with an IBR receiving PMRT from 13% to 
33% between 2004 and 2013103,158. PMRT has a negative impact on the cosmetic outcome after 
implant-based IBR and is linked to higher rates of surgical complications including 
postoperative infection, wound dehiscence, seroma, and skin flap necrosis58,159-163.  
While the formation of a capsule surrounding the breast implant is physiological and due to the 
inflammatory response to a foreign object, the late complications of capsular contracture refers 
to the fibrosis of the capsule, commonly induced by radiation and often associated with pain, 
impaired cosmetic outcome, lack of softness, and implant migration105,164-167. These effects 
may lead to psychological distress and impaired HRQoL167. The risk of capsule contracture is 
increased with bacterial contamination of the implant, type of implant and smoking. Capsular 
contracture occurs in approximately 20.0-40.4% following immediate and 17.0%-26.4% 






Figure 4. Postoperatively irradiated patient with 
implant-based IBR to the left breast.          





Irradiation in the context of implant-based IBR increases surgical revisions and implant failure, 
defined as implant loss with or without secondary autologous reconstruction163,165,166,170-173. A 
meta-analysis including 1105 women undergoing implant-based breast reconstruction showed 
a 4.2 times higher risk of surgical complications in women receiving radiotherapy166. Implant 
failure affects 11-37% of irradiated patients167,174-178. Some authors question whether offering 
IBR to patients planned for PMRT is ethically correct179, while it is internationally agreed that 
PMRT is no absolute contraindication for IBR in a well-informed patient99. From the patient’s 
own perspective, implant failure implies negative effects on HRQoL related to reoperation, 
pain and repeated hospital visits, loss of income, sick leave, re-admission to surgery for implant 
removal and probably a subsequent or later conversion to an autologous reconstruction with a 
new risk of postoperative complications, sick leave and recovery period. With this in mind, 
even though Eriksson et al reported on lower satisfaction with the overall outcomes after IBR 
among irradiated patients, still 77.7% of patients receiving PMRT after IBR and not suffering 
implant failure would recommend it to other women in the same situation175. 
 
1.3.4 Delayed breast reconstruction  
1.3.4.1 DIEP flap reconstruction 
Delayed breast reconstruction may be performed using implants or autologous tissue or a 
combination of both. It is also possible to convert an immediate breast reconstruction to a 
delayed autologous reconstruction at a later time in case of complications, patient preference, 
or unsatisfactory aesthetic results. In Sweden, delayed autologous breast reconstruction is 
recommended to be performed no earlier than two years after initial breast cancer surgery with 
the rationale that half of breast cancer recurrences will have occurred by then180,181. For the 
included study population in this thesis, autologous breast reconstruction was primarily offered 
to irradiated patients180. One of the most common methods of delayed autologous breast 
reconstruction in Sweden today is the deep inferior epigastric perforator (DIEP) flap.  
Breast reconstruction with perforator flaps started in the early 1970s with the knowledge that 
flaps of an increasing length-to-width ratio could be elevated safely183,184. This was soon 
followed by the development of the “free flap” technique, i.e. the free transfer of a non-pedicled 
tissue flap to the recipient site by microvascular anastomosis between perforator vessel stumps 
on the flap and adequate recipient vessels185,186. The transverse rectus abdominis myocutaneous 
(TRAM) flap was first introduced as a pedicled flap, and transfers one entire rectus abdominal 
muscle with an overlaying skin island; this, however, was often associated with donor site 
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complications including motor weakness, bulging, hernia, or weakness of the abdominal 
wall187. Therefore, the free TRAM flap was developed, using only of a limited piece of rectus 
abdominal muscle188,189. A further development of the method was the DIEP flap, first 
described in the U.S. in 1994 by Allen and Treece190. 
The DIEP flap is the adipose tissue and skin from the lower abdomen which is transposed to 
the mastectomy site as a free microsurgical transplant in order to rebuild the breast. In 1999, 
the method was described by Blondeel et al in Belgium who further popularized this 
technique191. The first DIEP flap reconstruction in Sweden was performed shortly thereafter 
and is today the first choice for free flap breast reconstruction with about 150-200 DIEP flap 













Figure 5. Patient operated with right deep inferior epigastric perforator flap reconstruction. Preoperative 
photograph (left side) and one-year postoperative result (right side).                                    
Photo:Ann-Charlott Docherty Skogh 
 
Major surgery can be classified as severe physical trauma since it exposes large wound surfaces 
and has been hypothesised to cause tumour progression in breast cancer patients192,193. Delayed 
breast reconstruction may thus increase the risk of breast cancer recurrence through reactivation 
of dormant micrometastases. Previous results are contradictory as study groups of 
heterogeneous reconstructive methods have been included, and most studies lacking any 
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matched control groups194-198. In a publication by Isern et al, tumour stage was not taken into 
account and the number of DIEP flaps was limited; furthermore, the rate of lymph node 
metastasis was significantly higher for the cases than the controls (66.4 versus 53.8%)197. Other 
studies could not find any increased risk of recurrence after autologous breast reconstruction194-
196,199,200. 
A summary of the studies investigating the risk of recurrence after autologous flap 
reconstruction are presented in Table 2194,195,197-203. Only two of these, however, exclusively 
include women with a DIEP flap reconstruction202,203. 
Table 2. A selection of studies investigating breast cancer recurrence after autologous flap 
reconstruction  
In Sweden, absolute contraindications for DIEP flap reconstruction are a BMI >30, active 
smoking and concomitant tumour recurrence or distant metastasis180,181. Relative 
contraindications include previous scars, e.g. after caesarean section or abdominoplasty casting 
doubt upon the integrity of perforators for the DIEP, diabetes, and cardiorespiratory 
comorbidities increasing surgical and on-table anaesthetic risk. Since year 2008, all patients 
planned for a DIEP flap reconstruction in Stockholm undergo screening for distant metastasis 
by contrast-enhanced chest and abdomen computed tomography (CT) scan. Preoperative CT 
angiography scan is further performed before the DIEP flap reconstruction in order to assure 
the existence and location of the perforating vessels arising from the deep inferior epigastric 














92 0-III 5.4% 
(local recurrence) 
None - 36.7 
Snoj 
(2006) 
156 I-III 18.6% 
(any recurrence) 
None - 66 
Isern 
(2011)  
125 I-III 32.8% 
(any recurrence) 
Mastectomy alone 















312 I-IV 12.5% 
(any recurrence) 
Mastectomy alone 
3.8% (any recurrence) 
0.08 137 
Wu (2016) 397 0-IV 2.8% 
(local recurrence) 
None - 43 
Svee 
(2018) 
225 I-III 12.9% 
(any recurrence) 
Mastectomy alone 













254 0-III 19.7% 
(any recurrence) 
Mastectomy alone 




1.4 BREAST CANCER RECURRENCE 
As metastatic disease is the major cause of breast cancer mortality, the primary aim of local 
and systemic therapy is to eradicate all active disease204,205. The shed of malignant cells into 
the circulation may potentially cause recurrence up to 20 years after surgical treatment205. 
Breast cancer is known for its propensity of late recurrences206,207, and tumour cells can 
disseminate from early epithelial alterations as well as from carcinoma in situ208. 
Asymptomatic circulating tumour cells (CTCs) are found in the blood of breast cancer patients 
without any signs of recurrences up to 22 years after initial diagnosis206. This contributes to 
breast cancer being viewed as a systemic disease, and once the disease has metastasized, it is 
considered incurable34. The vast majority of breast cancer-related deaths occur due to 
metastatic tumour growth impairing the function of vital organs34. 
 
1.4.1 Local and regional recurrence  
Local recurrence (LR) is defined as a recurrent tumour in the ipsilateral breast, be it at the 
original tumour site, ipsilateral skin or chest wall, often but not always carrying the same 
histopathologic features as the primary tumour. A recurrence in the ipsi- or contralateral 
axillary, infra- or supraclavicular, interpectoral or internal mammary lymph nodes is 
considered a regional recurrence (RR).  
Approximately 20-30% of patients with early-stage breast cancer experience recurrent disease 
despite advances in early detection and comprehensive treatments209,210. Recurrence rates vary 
depending on the stage of the disease, the subtype and treatment49,53,211-213. A meta-analysis 
from the EBCTCG suggests that breast cancer recurs at a steady rate throughout a period of 5 
to 20 years after diagnosis79. Still, approximately 80% of recurrences occur within the first two 
to five years after primary treatment211,214,215. Up to 30% of patients presenting with a LR may 
have underlying synchronous distant disease216. LR is associated with an increased risk for 
distant recurrence217-219 and breast cancer death220, which underlines the value of distant 
metastasis screening in these patients.  
The time to LR has been proposed to be a prognostic factor of survival218,221: If LR occurs more 
than 2-5 years postoperatively, survival figures are better compared with earlier LR222. It is 
therefore hypothesized that LR developing within five years after cancer surgery may represent 
metachronous second primaries in the breast rather than a recurrence of the index lesion223.  
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The incidence of LRR depends on the therapy given along with other established risk factors 
such as young age, late-stage diagnosis, dense breast tissue224, lymphovascular invasion, 
multifocality, lymph node involvement, histologic grade, and extensive associated ductal 
carcinoma in situ (DCIS)50,51,79,217,225-230. 
 
1.4.2 Distant metastasis 
A distant metastasis is defined as any other recurrence than LR and RR, most commonly 
localised to the skeletal system, the liver, the lung or the brain. The concept of tumour 
dormancy is supported by the fact that CTCs are detected in the blood of recurrence-free breast 
cancer patients up to 25 years after primary diagnosis231,232. CTCs may remain dormant until 
they are either reactivated or eliminated206. A reactivation may be initiated through new 
mutations, scattering of secondary micrometastases, and increased levels of cytokines and 
growth factors by trauma, illness or a new surgical procedure233,234. Lack of vasculature 
surveillance or inefficient immunosurveillance could further explain reactivation193,235-240. 
CTCs are suspected to originate from occult micrometastases231, and recent advancements 
allow the detection and quantification of CTCs in peripheral blood241,242. A meta-analysis by 
Wen-Ting et al included 6712 breast cancer patients from 50 studies and found specific 
treatment modalities such as neoadjuvant chemotherapy to associate with reduced of CTC-
positive rates, suggesting that CTCs can monitor treatment responses in breast cancer 
patients243. In patients with detectable CTCs, larger tumours, higher histologic tumour grade, 
and increased lymph node involvement are significantly more common than in CTC-negative 
patients241,244.  
 
1.4.3 Recurrence patterns  
The time to as well as the pattern of recurrence differs according to breast cancer subtype; slow-
growing ER-positive tumours are characterized with a prolonged period of DFS. The 
recurrence pattern for luminal A shows a slow risk increase reaching its peak after three years; 
in luminal B, however, most recurrences occur during the first five years245,246. The risk of 
recurrence in luminal tumours is relatively low but remains stable even after 10 years of follow-
up. These subtypes have the lowest rate of distant metastases, which are predominantly bone 




HER2-enriched tumours show a biphasic peak of recurrence: the first about twenty months 
after primary surgical treatment, with a greater risk if Ki67 is 14% or more, and the second 
peak after around 72 months, with a greater risk if Ki67 is lower than 14%245. HER2-enriched 
and TNBC tumours have the highest risk of recurrence during the first five years210. The HER2-
enriched subtype is associated with increased rates of locoregional recurrences and distant 
metastasis in bone, liver and brain210,246. 
 
Triple-negative tumours commonly have a high proliferation rate and their recurrence risk 
peaks at nearly 18 months. Less common variants of TNBC with a low proliferation rate 
display a continuous risk curve245. TNBC is associated with a predilection of distant metastasis 





1.5 SOCIOECONOMIC STATUS AND COMORBIDITY  
1.5.1 Socioeconomic status  
Socioeconomic status (SES) is a complex concept used broadly in the literature to cover factors 
including ethnicity, income, education, occupation type and housing247,248. SES is associated 
with the stage of breast cancer at diagnosis, and screening attendance for women with lower 
socioecomonic status is lower249. Individuals with a lower SES tend to receive chemotherapy 
less often, less expensive alternatives of endocrine treatment, and less extensive surgery250-252. 
Low socioeconomic status is further associated with worse breast cancer survival253,254. A 
Swedish study including 4 645 breast cancer patients showed, after adjustment for tumour size 
and age at diagnosis, that the risk of breast cancer death was 19% lower among women 
belonging to a household with a high compared to a low socioeconomic status (HR high versus 
low 0.81; 95% CI: 0.67-0.97)255.  
 
Also breast reconstruction is affected by socioeconomic factors, since women opting for breast 
reconstruction are more likely to be of higher socioeconomic status256-259. Received 
information on IBR prior to surgery is affected by patient ethnicity and education260. A 
systematic review showed that patients with lower median income and of lower socioeconomic 
groups are less prone to undergo any type of breast reconstruction256. Women with the highest 
probability of having an IBR are of caucasian origin, have a private health insurance, and live 
in areas with the highest rates of high-school education247,261,262. This was also valid in countries 
with general health care coverage of the reconstructive procedure, such as Canada and 
Denmark 256,263. In Sweden, having a current employment and a high income per household is 
significantly associated with an IBR, as is patient-reported perceived preoperative information 
and the feeling of being involved in the decision-making process264. 
 
1.5.2 Comorbidity  
Several definitions have been suggested for the term comorbidity, based on variations of a 
single core concept: the presence of more than one distinct health condition in an individual. 
Always used on a person level, distinctions are sometimes made based on the nature of the 
health condition, the relative importance of co-occurring conditions, and the chronology of 
their presentation265,266.  
 
Chronic diseases are more common among elderly patients, and cancer itself is a chronic 
disease with long-term consequences for health and quality of life, more prevalent among older 
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patients265. Underlying comorbidity among cancer patients is common, and data from the U.S. 
indicate that 40% of all cancer patients have at least one other chronic condition with the most 
common diagnoses being cardiovascular disease, metabolic illness, mental health disorders, 
and musculoskeletal conditions267. Fifteen percent have two or more chronic conditions267. 
 
Comorbidity affects cancer treatment since underlying comorbidity potentially affects cancer 
development, stage at diagnosis, treatment, and outcome of breast cancer patients268. Patients 
with comorbidities are less likely to receive immediate or delayed breast 
reconstruction257,262,263,269, to tolerate systemic treatment267,270 or radiotherapy271, and have 
lower BCSS as well as overall survival rates270,272. 
 
1.5.2.1 Charlson comorbidity index  
Charlson et al defined numerous clinical health conditions through reviewing hospital charts 
and assessing their relevance in the prediction of 1-year mortality. The Charlson Comorbidity 
Index (CCI) has since then been a useful tool for health researchers to measure the presence 
and severity of comorbid disease status273,274. The index provides an overall score for 
comorbidity based on complex values weighted by level of severity in 19 selected health 
conditions (myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular accidents, dementia, chronic obstructive pulmonary disease, connective tissue 
disease, peptic ulcer disease, mild/severe liver disease, uncomplicated /end-organ damage 
diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumour, 




1.5.3 Smoking  
Smoking is a well-known risk factor associated with comorbidity, level of education, SES, and 
cancer, making it a confounding factor important to take into consideration. It does not only 
associate with the presence of comorbidity, but also with the comorbid disease outcomes275,276. 
People living below the poverty level and people having lower levels of educational attainment 
have higher rates of cigarette smoking than the general population277-280. Smoking is associated 
with increased breast cancer risk281, and women with low and moderate levels of education 
show increased smoking habits along with an increased incidence of breast cancer, thereby 
suggesting an association between the two factors (HR=1.40, 95% CI 1.25-1.57 and HR=1.14, 
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95% CI 1.05-1.24, respectively)282. Current smokers have worse breast cancer survival 
(HR1.33; 95 % CI 1.28-1.38) when compared with former smokers and never-smokers (1.09; 
1.06-1.13)283,284.  
 
From a surgical point of view, smoking is associated with impaired wound healing and higher 
risk of infection285,286; longer periods of smoking cessation decrease the incidence of 
postoperative complications287. Since smokers experience postoperative complications such as 
flap loss, hematoma or fat necrosis more often than non-smokers288, DIEP flap reconstruction 
is performed on non-smokers only in Sweden.   
 
 
1.5.4 Body mass index 
With worldwide increasing rates of obesity, new challenges for surgeons are arising as high 
BMI is a proven risk factor in any surgery, including breast reconstruction289. Patients with a 
BMI >30  are more likely to experience surgical complications including wound dehiscence, 
hematoma, seroma formation, fat necrosis, partial or total flap failure, and hernia occurrence, 
as well as medical complications including deep venous thrombosis,  pulmonary embolism, 
myocardial infarction, pneumonia, urinary tract infection, sepsis, and stroke289. Some suggest 
a linear relationship between increasing BMI and overall complication rates, although serious 
complications defined as partial or total flap failure and medical events including 
thromboembolic or cerebrovascular events remain relatively uncommon even in morbidly 
obese patients290. Swedish recommendations state that patients receiving autologous 




1.6 HEALTH-RELATED QUALITY OF LIFE AND PATIENT-REPORTED 
OUTCOMES 
 
The term health-related quality of life (HRQoL) is multidimensional and was first introduced 
by the World Health Organization (WHO) in the 1950s. Health was then defined as “a state of 
complete physical, mental and social well-being, and not merely the absence of disease or 
infirmity”291. HRQoL consists of the four aspects including physical, emotional, cognitive and 
social function, and further the symptoms and difficulties related to the disease292. HRQoL 
should be estimated by the individual herself and can vary over time292.  
One way to estimate HRQoL in breast cancer patients is through measuring patient-reported 
outcomes (PROs), including self-assessment surveys to measure patients’ own perception of 
treatment outcomes. Such assessment may itself improve patient satisfaction with received 
care.   
There is a variety of instruments to measure PROs in breast cancer patients293,294, some of 
which are listed below:  
- Satisfaction and Body Image Questionnaires, (BREAST-Q)  
- European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire-Breast Cancer Module (EORTC QOL-C30 and QLQ-BR23) 
- Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B),  
- Satisfaction with Life Domains Scale for Breast Cancer (SLDS-BC),  
- Body Image after Breast Cancer Questionnaire (BIBCQ) 
- Hopwood Body Image Scale (HIBS) 
- Polivy Body Image Scale (PBIS) 
- Michigan Breast Reconstruction Outcomes Study (MBROS) 
- Breast Cancer Treatment Outcome Scale (BCTOS) 
- Breast Cancer Chemotherapy Questionnaire (BCQ) 
- Functional Assessment of Cancer Therapy-Endocrine System (FACTES) 
- Mastectomy Attitude Scale (MAS)  
- Breast Cancer Prevention Trial Symptom Checklist (BCPT)  
 
 
The results regarding HRQoL following implant-based IBR or autologous reconstruction are 
diverse, but the majority of studies show higher scores in reconstructed patients compared with 
those undergoing mastectomy alone96,117,120,156,295-317. A study by Jeevan et al, however, found 
that the long-term quality of life in patients undergoing immediate or delayed implant-based 
breast reconstruction was not better than in those undergoing mastectomy alone 318. Long-term 





BREAST-Q is a condition-specific instrument measuring PROs in breast surgery patients, and 
was first available in English in 2009321. It was translated into Swedish in 2012. The survey 
quantifies the pre- and postoperative effect of cosmetic and reconstructive breast surgery on 
HRQoL on six scales: physical, psychosocial and sexual well-being, and satisfaction with 
breasts, outcome, and care.  It provides meaningful and reliable information for use in both 
clinical practice and research321,322 and has been validated for the assessment of HRQoL in 
European women323-326. 
 
BREAST-Q offers specific modules for mastectomy, breast-conserving therapy and breast 
reconstruction which are distributed pre- and/or postoperatively (see Figure 6). Each subscale 
produces an independent score from 0 to 100 where lower values indicate lower well-being or 
satisfaction. The latest version of BREAST-Q, version 2.0, was launched in May 2015 and 
includes an additional subscale for adverse effects of radiation along with a question on 
lymphedema under the subscale for physical well-being.   
 
 
Figure 6.  The BREAST-Q version 1.0 is divided into a quality of life and a satisfaction domain, each 







2 AIMS OF THE THESIS 
 
The specific aims were: 
 
I. To evaluate the oncological safety of nipple-sparing mastectomy by comparing its local 
recurrence rate with that after conventional mastectomy. 
 
II. To evaluate the oncological safety of DIEP flap reconstruction by estimating the 
associated risk of breast cancer recurrence and comparing it with a matched control 
group of patients undergoing mastectomy without any delayed reconstruction. 
 
III. To explore the associations between socioeconomic status, comorbidity and survival 
outcomes in patients undergoing DIEP flap reconstruction compared with a matched 
control group of patients undergoing mastectomy without any delayed reconstruction.  
 
IV. To investigate the long-term effects of radiotherapy as measured by rates of implant 
failure and patient-reported outcomes, and investigate the frequency of reoperations 








3 PATIENTS AND METHODS 
3.1 COHORT STUDY DESIGN 
Population-based studies investigate a defined population and aim to generate results that are 
generalisable to the entire population addressed in the study and not merely the included study 
population. One form of population-based investigation is the cohort study design, in which 
the study population (the cohort) is biased on a specific exposure and followed for a period of 
time. The outcome of interest is registered in exposed and unexposed individuals during the 
follow-up period and incidence rates in both groups then compared. Cohort studies represent a 
fundamental study design in epidemiology used in several scientific fields, and can be either of 
retrospective or prospective nature. In cohort studies, unlike clinical trials, there is no 
intervention, treatment or exposure administered to the study population, thereby classifying it 
as an observational study design. Common characteristics of the cohort are often controlled for 
in the statistical analysis, and both exposure and control variables are measured at baseline. 
Risk factors are studied without subjecting participants to those risk factors but rather by 
collecting data based on the individual lifestyle habit such as incidental exposure risk factors 
or self-administered exposure (such as smoking). Regression analysis can later be used to 
evaluate the extent to which the exposure or treatment variable contributes to the outcome of 
interest, while accounting for other contributing covariates.  
 
3.1.1 Matched cohort design 
In a matched cohort study, the exposed case is matched with one or several unexposed controls 
with regard to a chosen set of matching variables such as age, calendar year, gender, or 
residential area. As a result of the matching procedure, these matching variables have an equal 
distribution in both groups and thus no effect as confounders; in that manner, a study design 
may get as close to a randomized controlled trial as possible. Hazard ratios can subsequently 
be calculated for suspected risk factors, without the effect estimates being influenced by the 
confounding effect of the matched covariates. A difficulty in matching procedures is the effort 






3.2 SWEDISH REGISTERS AND DATA SOURCES FOR THIS THESIS 
3.2.1 Swedish Personal Identity Number  
All Swedish citizens are given a unique 12-digit personal identity number (PNR) at birth, 
thereby enabling crosslinking between a large number of Swedish national registers which are 
an invaluable resource to medical research. The PNR further enables tracking of individual 
medical records across health care services enabling population-based epidemiological 
research327. 
 
3.2.2 The National Quality Register for Breast Cancer 
Whereas the Swedish Cancer Register includes data on date of diagnosis, invasiveness, clinical 
TNM stage and SNOMED coding for histological data on all tumour types, the National 
Quality Register for Breast Cancer (NKBC) provides detailed information specifically for 
breast cancer, including date and method of diagnosis, age, gender, invasiveness, tumour and 
lymph node characteristics, type of surgery, pathological data, and neoadjuvant or adjuvant 
treatment regimens. The register is updated according to information from the Total Population 
Register (TPR), the Swedish Cancer Register and the Swedish Cause of Death Register and 
provides nationwide coverage since 1992. In 2007, a harmonised online reporting platform was 
developed (Informationsnätverk för Cancervården, INCA) to enable an entirely digital data 
flow. The NKBC has a high validity of over 90%328. Registered treatments have been validated 
against medical charts, and a 94-96% of completeness and agreement was found329. 
  
For study I-II, variables extracted from the NKBC include date of diagnosis, date of 
mastectomy, tumour size in mm, clinical and pathological tumour stage, invasiveness, 
clinical and pathological axillary lymph node status, ER and PgR status (both available from 
2001), Nottingham histological grade (NHG, available from 2004), HER2 status (available 




3.2.3 Registers maintained by Statistics Sweden 
Statistics Sweden, established in 1858, maintains national registers on Swedish statistics such 
as the Total Population Register (TPR) and the Longitudinal Integration Database for Health 
Insurance and Labour Market Studies (LISA). The LISA database further harbours the Swedish 
Register of Education, the Swedish Occupational Register and the Register on Income and 
Taxes (IoT).  
3.2.3.1  The Total Population Register  
The Total Population Register is a nationwide register maintained by Statistics Sweden, 
covering all individuals in Sweden since 1986. It includes anyone born in Sweden or intending 
to live in Sweden for more than one year327. This register is updated continuously, providing 
information on Personal Identity Number, gender, birthdate, marriage and partnership, 
residency, country of birth, migration in and out of Sweden, and date of death.  
3.2.3.2 Longitudinal Integration Database for Health Insurance and Labour Market 
Studies 
The LISA database integrates data from the labour market and educational and social sectors 
that were held as separate registers such as the Income and Taxes (IoT), the Swedish Register 
of Education and the Swedish Occupational Register until 1990, and is updated each year. This 
national register includes all individuals above 16 years of age. More specifically, it provides 





3.2.4 Registers maintained by the National Board of Health and Welfare  
The governmental agency National Board of Health and Welfare is responsible for Swedish 
statistics concerning health and disease, including health care and causes of death.  
 
3.2.4.1 The Swedish National Patient Register 
The Swedish National Patient Register (NPR) is maintained by the National Board of Health 
and Welfare and was founded in 1964. Since 1987, complete coverage has been assured with 
more than 99% of all somatic and psychiatric discharge codes. The NPR further includes 
patient and geographic data, as well as administrative data about the in-hospital stay, and 
medical data. Diagnoses at hospital discharge are forwarded electronically to the NPR in a 
standardized procedure. Each discharge generates World Health Organization International 
Classification of Diseases-10th Revision (ICD-10) codes with main and contributory diagnoses 
specified. The validity of the register has been shown to be high330.   
 
For study III, data on diagnoses for calculation of the Charlson Comorbidity Index were 
extracted from the year prior to reconstruction or corresponding reference date and onwards. 
Up to 30 ICD-10 codes were obtained per case along with ICD-10 procedure codes.   
 
Data on tumour characteristics, treatment, recurrence and death were verified by individual 
review of medical charts for all studies included in this thesis.    
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83 overlapping cases  
Studies II – III: 
All DIEP flap reconstructions at 
Karolinska University Hospital 
Stockholm 1999-2013 
N=254 
Matched controls (age, TNM-
stage and year of mastectomy) 
without delayed reconstruction 
N=729 
31 overlapping cases  
47 overlapping cases  
Study I: 
All NSM with IBR at 
Karolinska University 
Hospital 2000-2012  
N=69 
Matched controls (age, 
TNM-stage, and year of 
mastectomy) conventional 










3.4 STUDY I 
 
Study I was a retrospective matched cohort study and included all breast cancer patients 
operated by therapeutic NSM and IBR at Karolinska University Hospital in Stockholm in 2000-
2012. For each NSM patient, three matched controls were assigned with matching on TNM 
stage, year of mastectomy and age at mastectomy. Controls were breast cancer patients 
undergoing conventional mastectomy alone and were identified through the NKBC at the 
Regional Cancer Centre (RCC) in Stockholm.  
 
Patients were divided into three age groups and two periods regarding the year of surgery. In 
case of neoadjuvant chemotherapy, matching used the preoperative clinical TNM stage. All 
preoperative mammography images of the NSM group were reviewed by a breast radiologist 
in order to define the radiological shortest distance (in mm) between the tumour border and the 
base of the nipple, defined as the tumour-nipple distance (TND).   
 
Local recurrence (LR) was set as the primary endpoint. All histologically proven recurrent 
breast cancer in the ipsilateral skin, chest wall, or the nipple-areola-complex was categorized 
as LR. Apart from local recurrence-free survival (LRFS), BCSS, OS and disease-free survival 
(DFS) were assessed. Patients whose NAC had been removed postoperatively, i.e. due to a 
surgical complication or a positive retroareolar biopsy, were excluded from analyses. 
 
  
Covariates collected for study I: 
Birthdate, date of mastectomy, clinical and pathological tumour stage, invasiveness, invasive 
tumour size, mastectomy side, year of mastectomy, NHG, ER and PgR status, HER2 status, 
tumour multifocality, type of axillary surgery, number of lymph node examined, number of 
positive lymph nodes, TND, adjuvant radiotherapy, neo-/adjuvant chemotherapy, neo-/adjuvant 
endocrine therapy, neo-/adjuvant targeted therapy, LR, RR, distant metastasis, contralateral breast 
cancer, overall and breast cancer death, date of death, last date of follow-up, and date of medical 





















Figure 8. Flowchart for the inclusion in studies II and III. DIEP, deep inferior epigastric perforator 
flap; SGAP, superior gluteal artery perforator; TRAM, transverse rectus abdominis myocutaneous; 
TMG, transverse musculocutaneous gracilis. 
 
Studies II and III are both based on the same retrospective matched cohort design including all 
patients with a previous mastectomy for breast cancer subsequently operated with a delayed 
DIEP flap breast reconstruction at the Department of Reconstructive Plastic Surgery at 
Karolinska University Hospital, Stockholm, between January 1999 and December 2013 (DIEP 
group). Patients in the DIEP group were matched to non-DIEP patients, i.e. breast cancer 
patients with a mastectomy but no delayed breast reconstruction, on the matching criteria year 
of and age at mastectomy, tumour stage, neoadjuvant therapy, and lymph node status.  
Each DIEP patient was assigned a reference interval corresponding to the time between the 
date of mastectomy and the date of DIEP flap reconstruction. An index date based on individual 
Patients included in final 
analysis: 
DIEP group N=254 
Control group N=729 
DIEP group










Treated for primary 
























reference intervals for each DIEP case was applied to find three matched controls per DIEP 
case.  
The primary endpoint was breast cancer-specific survival (BCSS). Secondary endpoints were 
OS and DFS. All included patients were free of recurrence and free of any other disseminated 
malignancy between the date of mastectomy and the date of DIEP reconstruction or the 
corresponding reference date. 
 
In study II, patients undergoing an immediate implant-based breast reconstruction (IBR) had 
not been excluded since IBR does not affect the primary outcome, survival. Those IBR cases 
were thus also included in study III since it is based on the same cohort. Sensitivity analyses 
were carried out in order to analyse the impact of IBR on both OS and BCSS.  
In study III, individual data on socioeconomic factors were obtained from Statistics Sweden 
and data on comorbidity from the National Board of Health and Welfare. Three-digit ICD-10 
codes were assigned to the groups of diagnoses used in the Charlson Comorbidity Index (CCI) 
273,274. The breast cancer diagnosis itself was not included in the CCI score. 
Covariates collected for study II: 
Birthdate, date of mastectomy, date of DIEP flap reconstruction, tumour stage, invasive tumour 
size, histological tumour type, BMI, smoking, mastectomy side, NHG, ER and  PgR status, HER2 
status, multifocality, type of axillary surgery, number of lymph nodes examined, number of 
positive lymph nodes, adjuvant radiotherapy, neo-/adjuvant chemotherapy, neo-/adjuvant 
endocrine therapy, neo-/adjuvant targeted therapy, surgical and medical complications, 
reoperations and revision surgery, LR, RR, distant metastasis, contralateral breast cancer, overall 
and breast cancer death, date of death, last date of follow-up, and date of medical chart review.   
Additional covariates collected for study III 
Disposable household and individual income, family status (i.e. living in a partnership or in a 
single household), highest level of education attained, occupation, country of birth, country of 
birth for parents, and up to 30 ICD-10 codes per case. 
 
40 
3.5.1 Timescales for investigated endpoints studies I-III 
In study I, LRFS was calculated from the date of mastectomy until the date of a local recurrence 
diagnosis, or to any first event of any local, regional or distant recurrence (disease-free survival, 
DFS). BCSS was calculated from the date of surgery to the date of death due to breast cancer, 
and OS was calculated from the date of surgery to the date of death from any cause. 
In study II-III, survival was calculated from the date of DIEP reconstruction, or the index date, 
until the date of any first local, regional or distant recurrence [DFS], the date of death due to 
breast cancer [BCSS], or the date of death by any cause [OS], respectively.  
In the absence of any event, cases were censored at the date of last clinical follow-up for LRFS 
and DFS, and last medical chart review for BCSS and OS. 
 
3.6 STUDY IV 
Study IV is a follow-up on a previously published retrospective cohort study by our group 175. 
The cohort consists of all breast cancer patients operated with a therapeutic mastectomy and 
implant-based IBR between January 2007 and December 2011 at Stockholm’s four main 
hospitals (Karolinska University Hospital, Capio St. Göran’s Hospital, Southern General 
Hospital, and Danderyd Hospital). Three groups were identified: those not receiving any 
radiotherapy (RT), those who had received RT prior to IBR (i.e. after previous breast-
conserving surgery or due to other malignancies), and those with post-mastectomy RT. 
The primary endpoint was IBR failure, defined as the removal of the implant due to surgical 
complications or patient preference, with or without a simultaneous or subsequent autologous 
reconstruction. Secondary endpoints were PROs, the number of unplanned reoperations and 




3.6.1.1 Patient-reported outcomes 
The BREAST-Q postoperative reconstruction module with subscales for satisfaction with 
breasts and with overall outcome, psychosocial, sexual and physical well-being was used. In 
order to enable comparison with the scores from 2012, the BREAST-Q version 1.0 was applied 
again. Questionnaires were sent out approximately eight years after the previous investigation. 
Postal addresses were obtained from the Swedish Tax Agency.   
Covariates collected for study IV:  
Birthdate, date of mastectomy/IBR, tumour stage, invasive tumour size, mastectomy side, year of 
mastectomy,  NHG, type of axillary surgery, number of lymph nodes examined, number of positive 
lymph nodes, radiotherapy, neo-/adjuvant chemotherapy, neo-/adjuvant endocrine therapy, 
neo/adjuvant targeted therapy, contralateral breast cancer, conversion to autologous reconstruction, 
recurrence, overall and breast cancer death, date of death, date of last follow-up and date of medical 
chart review. Radiotherapy details included irradiation field, fractions, cumulative dose, and date of 
last given fraction. 
Postoperative surgical complications: postoperative infection and reoperations for deep infection or 
bleeding, implant removal, and non-surgically treated complications such as infection, hematoma, 
and seroma.  
Revisional surgery regarded the ipsilateral breast, i.e. capsulectomy, implant exchange, abdominal 
advancement flap, nipple reconstruction, liposuction, lipofilling, and scar revision. Contralateral 
symmetrizing procedures included mastopexy, breast reduction, and implant-based augmentation.  
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3.7 STATISTICAL ANALYSES 
The normal distribution of data was tested through the Shapiro–Wilks test, and parametric or 
non-parametric tests were used accordingly. For continuous variables, mean or median values 
were reported with their standard deviation and range, respectively. In case on non-normal 
distribution, Mann-Whitney or Kruskal Wallis tests were applied for two-group or three-group 
comparisons, respectively. Categorical data are presented as case numbers, and their 
distribution in the groups was tested by Pearson’s Chi square test or Fisher’s exact test.  
The reported P-values are two-tailed, with a P-value of <0.05 considered significant. SPSS® 
version 24-26 (IBM, Armonk, New York, USA) and Stata version 16 (StataCorp, Lakeway 
Drive, Texas, USA) were used for all statistical analyses, and resulting databases were 
registered and managed in accordance with the European General Data Protection Regulation. 
 
3.7.1 Survival analyses  
Survival analyses can be applied on any event of interest, not merely death, comparing binary 
outcomes between two groups of exposed versus unexposed individuals. Since survival 
analyses are so called time-to-event analyses, a timescale must be predefined. Depending on 
the outcome of interest, the timescale could include different definitions such as follow-up 
time, attained age, etc. For follow-up, time zero represents the start of the observation time. In 
all our studies, time zero was set at time of reconstruction, either immediate or delayed. 
Each case further contributes to person-time until the occurred event of interest or until the time 
the case is removed, i.e. censored, due to drop-out or loss to follow-up, or until the end of 
follow-up time. Merely comparing the number of outcomes at the end of the follow-up period 
would not account for variations in person-time contributed by each case and would hence give 
misleading results. The censoring in survival analysis should not be related to the probability 
of the event of interest, i.e. it should be unrelated to the outcome, so called non-informative 
censoring.  
One type of survival analysis is the use of Kaplan-Meier survival estimates, used in all studies 
of this thesis. The Kaplan-Meier model estimates the survival function over time and thereby 
the risk of an event by quantifying the time until the occurrence of the event. The estimated 
survival curves can be plotted overall or by groups of interest and in order to do so, the status 
at the last observation and the start and end date of follow-up time must be included for all 
cases. The plot will display a step-wise declining function as events occur, and censored cases 
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are denoted by small vertical marks. In this thesis, survival proportions were calculated 
according to the Kaplan Meier model, and the log rank test or Wilcoxon test were applied 
accordingly to compare groups. Due to the declining number of cases over time, the estimated 
probability of survival is more precise at the start than towards the end of follow-up. Another 
limitation of the Kaplan-Meier survival model is that it does not account for the associations of 
the outcome with several covariates (multivariable analysis), and further methods such as the 
Cox proportional hazard regression model must then be applied. 
3.7.1.1 Cox proportional hazards regression model 
Another method of survival analysis is the Cox proportional hazards regression model. Also in 
Cox proportional hazards regression, the timescale must be predefined. The advantage of this 
method is that the association of several covariates with the outcome can be assessed and 
adjusted for. No assumption about the shape of the hazard is made, and the baseline hazard in 
a Cox regression model is hence unknown but considered equal for all cases. The regression 
model assumes, however, that hazard is proportional for each time point. Since this assumption 
cannot always be fulfilled, it should be assessed before the performance of analyses. One way 
of doing this is by visually assessing the plot of Schoenfeld’s residuals against time. Another 
assumption made by the Cox proportional hazards model is that censoring is non-informative. 
In study II-IV, Cox proportional hazard regression was applied to assess the association of risk 
factors with the relevant endpoints.  
In study II-III, uni- and multivariable Cox proportional hazards regression analyses were 
carried out to assess associations of comorbidity (categorized through the CCI score), 
socioeconomic factors (including disposable income per household, family status, highest level 
of education and occupation), and clinical data (year of and age at mastectomy, tumour stage, 
lymph node status, hormone receptor status, radio- and chemotherapy) with OS and BCSS.  
In study IV, uni- and multivariable Cox proportional hazards regression were applied to test 
risk factors for IBR failure. The proportional hazards assumption was checked through 
statistical testing and graphical diagnostics based on the global test of Schoenfeld’s residuals 
without any evidence of time-varying hazards. Results are presented as hazard ratios (HR) with 






4.1 STUDY I 
A total of 275 mastectomies were included in the study; 69 (in 67 patients) in the NSM group 
and 206 (in 203 patients) in the control group. The median age was similar between both 
groups: 49 years (24-74) for the NSM group and 48.5 years (21-87) for the control group (P= 
0.384). There were no statistically significant differences between the two groups regarding 
neoadjuvant or adjuvant oncological treatment. Median follow-up time was 36 months (range 
4-162) for the NSM group and 35 months for the control group (range 1-160; P= 0.969). The 
TND measurements could be re-assessed in 56 out of 69 in the NSM group, and the median 
TND was 49.5 mm (1-120 mm). NSM patients operated 2010-2012 showed a trend towards 
shorter median TND than those operated 2000-2009 (4.9 versus 5.3 cm, P=0.590). The NAC 
was successfully preserved in 64 out of 69 cases. 
 
4.1.1 Breast cancer recurrence and survival  
Breast cancer recurrence occurred 29 cases during follow-up: three in the NSM group (one 
regional relapse which coincided with distant metastases, one isolated regional relapse and 
another case of distant metastasis) and 26 in the control group. No LR (including NAC 
recurrences) were registered in the NSM group throughout the entire follow-up period whereas 
seven LR were reported in the control group (P=0.140). Median time to LR was 11 months 
(range 3-92). An additional five regional and 19 distant recurrences were registered in the 
control group. The 5-year DFS was 94.1% in the NSM group and 82.5% in the control group 
(log rank P=0.068; see Figure 9). 
Death of any cause occurred in twenty-three cases, thirteen of which were due to breast cancer. 
Two cases of death due to any cause were registered in the NSM group, including one breast 
cancer death. Twenty-one deaths of any cause were registered in the control group,  twelve of 
which were breast cancer deaths. The estimated 5-year OS was 96.2% in the NSM group and 
91.3% in the control group (log rank P=0.166). Five-year BCSS was 98.0% in the NSM group 







Women at risk 
 
Figure 9. Kaplan-Meier survival curves for BCSS (left) and DFS (right) with the blue curve 
representing the NSM group and red curve the control group in both plots. Log rank P=0.244 (BCSS) 
and P=0.068 (DFS). 
 
 
4.2 STUDY II  
The cohort in studies II-III consisted of 983 patients: 254 DIEP flap reconstructions matched 
to 729 controls. The median time from mastectomy to DIEP flap reconstruction was 36 (range 
12–220) months, with a median follow-up of 89 (range 4–214) months following DIEP flap 
reconstruction and 75 (0–367) months (P=0.053) in the control group. The median invasive 
tumour size was similar in both groups: 28.5 mm (1–100) and 30 mm (1–170), respectively 
(P=0.540). The median time between DIEP flap reconstruction/index date and breast cancer 
recurrence was 74.5 and 60.5 months, respectively (P=0.339).  
 
4.2.1 Breast cancer recurrence and survival  
A total of 224 recurrences were registered, with similar proportions for both groups: 50 (19.7%) 
recurrences in the DIEP group and 174 (23.9%) in the control group (P=0.171). Eleven (4.3%) 
LR occurred in the DIEP group and 31 (4.3%) in the control group (P=0.958). RR were 
NSM 69 62 53 41 33 23 14 
Control 
group 
206 193 162 124 93 86 75 
    69 59 47 34 22 15   8 
   204 162 126 95 69 54   43 
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registered in eight (3.1%) and 33 (4.5%) cases, respectively (P=0.344), while distant recurrence 
developed in 43 (16.9%) and 149 (20.4%) cases, respectively (P=0.224).  
Thirty-seven (14.6%) deaths due to any cause were registered in the DIEP group and 188 
(25.8%) in the control group (P<0.001), with a 5-year overall survival of 91.6% and 84.7%, 
respectively (log rank P<0.001; see Figure 10). Breast cancer death was reported in 33 (13.0%) 
women in the DIEP group and 132 (18.1%) in the control group (P=0.060). Unadjusted Kaplan 
Meier estimates showed a 5-year BCSS of 92.0% and 87.9% (log rank P=0.032; see Figure 
10).  Independent risk factors for death due to breast cancer are reported in Table 3. After 
adjustment for tumour and patient characteristics and treatment, the lower OS persisted for the 
control group. This was, however, not seen for BCSS.  With these results in mind, we planned 
study III in order to investigate potential underlying differences between the two cohorts, such 
as SES or comorbidity. 
 
 
Figure 10. Unadjusted Kaplan-Meier survival curves for BCSS (left) and OS (right) with the blue 
curve representing the DIEP group and the green curve the control group in both plots. Log rank 
P=0.032 (BCSS) and P<0.001 (OS).   
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4.3 STUDY III 
The cohort in study III is identical to the one in study II. The results presented in Table 4 suggest 
that the DIEP group represents a population with a higher SES, since a lower proportion of 
individuals with primary school as the highest level of education or a low income were seen 
(Table 4). The DIEP group had a significantly lower prevalence of congestive heart failure, 
diabetes mellitus and chronic obstructive pulmonary disease, and lower overall CCI scores  
compared with the matched control group.   
Interestingly, we found that significantly more cases in the control group than the DIEP group 
had previously undergone IBR (149 cases (20.4%) versus 21 cases (8.3%), P<0.001). We 
therefore compared women without IBR from the control group with women with IBR from 
both groups, and found that the IBR patients had characteristics similar to the DIEP group. 
Women with an IBR had more often higher education levels (postsecondary > 3 years, 40.6% 
versus 26.8%, P=0.001) and a high disposable household income (46.5% versus 28.1%, 
P<0.001), and worked more often as clerks/civil servants (62.3% versus 35.3%, P<0.001).  A 
majority of women undergoing IBR were in the lowest CCI group (CCI group 0-6: 90.0% 
versus 67.2%, P<0.001). The differences between the DIEP and the control group persisted, 
however, when excluding all IBR cases from the analysis of socioeconomic characteristics and 
comorbidity. The control group had a higher crude risk of death of any cause (HR 2.08, 95% 
CI 1.40-3.09), which persisted despite adjustment for clinicopathological factors, SES and 
comorbidity (HR 1.88, 95% CI 1.24-2.86). Younger age at mastectomy, being retired or 
unemployed, and having a CCI score ≥ 7 were further presented as independent risk factors. 
On sensitivity analyses excluding all women with IBR, similar results were found. 
For BCSS, the higher crude risk of breast cancer death (HR1.62, 95% CI 1.07-2.46) in the 
control group did not persist in adjusted analyses. When we excluded all IBR cases from 
multivariable analysis, however, BCSS was significantly lower for the control group (HR 1.79, 
95% CI 1.09-2.92). Independent risk factors for death due to breast cancer were younger age 
at mastectomy, working as a labourer or being unemployed, and a CCI score ≥ 7. 
 
 49 
Table 4. Socioeconomic data and comorbid conditions comparing the DIEP and control 
groups. 
  
 DIEP group 
 (n = 254) 
Control group 
 (n = 729) 
P-value  










 311 (42.7) 
12 (1.6)  
0.024* 
Own birth country  
Sweden 
Europe, not Sweden 













Highest level of education  
Primary school 
Secondary school  
Postsecondary school, < 3 years 
Postsecondary school, > 3 years 
Missing 
 










































































































4.4 STUDY IV  
 
A total of 754 implant-based immediate breast reconstructions (IBR) in 729 women were 
included. The cohort was divided into radiotherapy (RT) groups: 386 non-irradiated IBRs, 64 
IBRs after previous RT, and 304 IBRs receiving PMRT. Median follow-up time was 120 
months (range 1-171 months) and did not differ between RT groups (P=0.111). 
 
IBR failure, defined as implant removal due to any cause with or without an autologous 
reconstruction, occurred after 128 IBRs (17%). Significantly higher proportions of IBR failure 
were registered in irradiated breasts, specifically in those which had been subjected to RT prior 
to IBR. Risk factors for IBR failure are presented in Table 5. We found prior or postoperative 
RT, age > 50 years at the time of IBR,  BMI ≥ 25, and surgical complication after IBR to be 
independent risk factors for IBR failure while being operated with permanent implants was 
negatively associated with IBR failure.  
 
At least three unplanned reoperations were performed in 98 out of 751 IBRs: 7.8% in the non-
irradiated group, 7.8% in the prior RT and 20.8% in the postoperative RT group (P<0.001). 
Minor or major surgical postoperative complications were registered after 223 (29.6%) and 40 
(5.3%) IBRs, respectively, and the rate of complications did not differ between the groups.    
 
BREAST-Q questionnaires were sent out to all patients alive who had not reached the primary 
endpoint IBR failure according to medical charts. In total, 540 patients were eligible, 390 of 
whom returned the survey. The response rate was thus 72.2%. A higher proportion of smokers 
(19.3 versus 12.3%, P=0.045) and of women suffering a breast cancer recurrence (12.7 versus 
5.6%, P=0.006) was found among non-responders. Within-group longitudinal analysis of 
BREAST-Q scores showed a significant decrease in mean scores for satisfaction with breasts 
and with overall outcome in the non-irradiated group (P<0.001 and P=0.004), while an increase 
in mean score was found on the psychosocial well-being subscale for postoperatively irradiated 
cases (P=0.011, see Table 6). On adjusted linear regression analysis of differences between RT 
groups based on the 2020 survey, women who had received prior RT scored lower on all 
subscales except for psychosocial well-being. Women in the postoperative RT group, however, 




Table 5.Uni- and multivariable Cox regression analyses with IBR failure as outcome variable, defined 
as implant removal due to any cause, with or without a contemporary or subsequent autologous 
reconstruction. Analyses include only cases with non-missing information in all covariates in both 
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Radiotherapy group        
No RT 362 34 1.00 (reference) 1.00 (reference)   
Prior RT  54 18 4.32 (2.44-7.65) <0.001 4.65 (2.55-8.45) <0.001 
Postoperative RT 299 73 2.87 (1.91-4.31) <0.001 3.42 (2.24-5.23) <0.001 
Smoking         
No  605 98 1.00 (reference)   1.00 (reference)   
Yes 110 27 1.59 (1.04-2.44) 0.033 1.33 (0.86-2.06) 0.199 
BMI        
<25 460 63 1.00 (reference)  1.00 (reference)    
≥ 25 255 62 1.96 (1.38-2.78) <0.001 1.49 (1.03-2.14) 0.034 
Age at IBR        
≤40 years 147 17 1.00 (reference)  1.00 (reference)   
41-50 years 271 41 1.35 (0.77-2.38) 0.295 1.54 (0.86-2.75) 0.146 
51-65 years 240 53 2.05(1.19-3.54) 0.010 2.59 (1.43-4.67) 0.002 
≥66 years 57 14 2.41 (1.19-4.89) 0.015 2.63 (1.23-5.61) 0.012 
Type of implant        
Temporary expander 236 44 1.00 (reference)   1.00 (reference)  
Permanent expander 311 61 1.06 (0.72-1.57) 0.754 0.92 (0.62-1.38) 0.691 
Permanent implant  168 20 0.59 (0.35-0.99) 0.047 0.47 (0.27-0.83) 0.009 
Surgical complications          
None 464 48 1.00 (reference)   1.00 (reference)   
Minor 212 58 2.94 (2.00-4.31) <0.001 2.76 (1.87-4.08) <0.001 
Major  39 19 7.21 (4.24-12.28) <0.001 8.84 (5.09-15.36) <0.001 
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Table 6. Each BREAST-Q subscale in the three radiotherapy groups is presented for both surveys, i.e. 
2012 and 2020. Change in mean from the first to the second survey is shown, as well as the results of a 
















Satisfaction with breasts       
Non-irradiated   217 59.30  55.30 -3.97 <0.001 
Prior RT 21 46.50 43.50 -3.00 0.279 
Postoperative RT 144 52.04 52.64 0.60 0.615 
Satisfaction with overall outcome       
Non-irradiated   216 71.36 67.68 -3.68 0.004 
Prior RT 21 58.59 52.77 -5.82 0.242 
Postoperative RT 144 65.79 66.66 0.87 0.554  
Psychosocial well-being       
Non-irradiated   203 73.12 72.38 -0.75 0.590  
Prior RT 21 61.41 62.41 1.00 0.752 
Postoperative RT 144 65.70 69.81 4.11 0.011 
Sexual well-being        
Non-irradiated   177 56.50 54.53 -1.97 0.189 
Prior RT 21 42.57 35.48 -7.10 0.053 
Postoperative RT 138 49.06 49.21 0.15 0.938 
Physical well-being        
Non-irradiated   203 80.23 81.09 0.87 0.360 
Prior RT 21 73.36 75.09 1.73 0.457 





In this thesis, two common breast reconstruction methods were investigated: immediate 
implant-based breast reconstruction and delayed DIEP flap reconstruction. Firstly, oncological 
safety in terms of recurrence risk and survival was assessed. Secondly, we added aspects of 
socioeconomic status (SES) and comorbidity to the oncological outcomes in patients 
undergoing delayed DIEP flap reconstruction. Finally, we investigated the effects of prior or 
postoperative radiotherapy (RT) on immediate implant-based breast reconstruction, reporting 
IBR failure rates, number of unplanned reoperations and patient-reported outcomes (PROs).  
In study I, survival was better in NSM patients with IBR than in the matched control group. 
The same was found in study II which included patients undergoing delayed DIEP flap 
reconstruction, despite satisfactory matching procedures in both studies. In study III, a 
stronger socioeconomic status and a lesser degree of comorbidity were found in DIEP patients 
compared with the matched control group; the superior survival was retained despite 
adjustment for these factors. Study IV presents a long-term follow-up of a large cohort of 
breast cancer patients with implant-based IBR showing that both prior and postoperative RT 
significantly increase the risk of IBR failure and negatively affect patient-reported outcomes. 
 
There are no national data on the number of delayed DIEP flap reconstructions performed in 
Sweden. In Stockholm, fewer delayed DIEP flap reconstruction than implant-based IBR are 
performed, and the DIEP procedure was initially reserved for irradiated patients and those 
experiencing IBR failure. This may, however, be different to other Swedish regions: In a recent 
Swedish study, wide regional variations in breast reconstruction patterns were reported, 
possibly due to limited availability of plastic and breast surgeons and the lack of standardized 
indications for breast reconstruction. Of 2904 mastectomy patients responding to the 
questionnaire, 31% reported having had a breast reconstruction (implant-based in 58% , 
autologous in 31% and methods of reconstruction unknown in 11%), which was most 
commonly (80%) performed in a delayed setting. Radiotherapy and older age was found to 
negatively associate with receiving breast reconstruction, even though autologous delayed 






5.1 RECURRENCE AND SURVIVAL 
In both study I and II, higher proportions of recurrence were found in the control groups. 
While Benediktsson and colleagues found high proportions of LR and NAC involvement in 
the setting of NSM145, the majority of studies confirm that NSM is an oncologically safe 
procedure with low local recurrence rates93,134,142,147. Coopey and colleagues attributed the low 
recurrence rates among NSM patients to improved patient selection over time since positive 
subareolar biopsies were shown to decrease93. Our results are hence in line with others, 
suggesting that NSM with subsequent implant-based IBR can be considered an oncologically 
safe procedure with no adverse effect on cancer-specific outcomes154,155. 
 
For delayed DIEP flap reconstruction, the oncological safety has been a subject of concern 
since surgical trauma and postoperative complications may exert systemic inflammatory 
effects which are hypothesized to negatively influence the oncological outcome332-335. Some 
previous studies have suggested higher recurrence rates after large flap reconstructions197,198, 
while other studies, none of which specifically investigated DIEP flap reconstruction, did not 
confirm any increased recurrence risk199,201. In study II, we found no evidence of an increased 
recurrence risk after delayed DIEP flap reconstruction, which is supported by results from 
another matched cohort study from the Uppsala region in Sweden202. Here, a higher proportion 
of patients in the DIEP cohort than in the no-DIEP cohort received adjuvant treatment 
(P<0.0001), which is concordant with our findings, as was the overall local recurrence rate. 
Thus, we delivered further evidence that DIEP flap reconstruction is not associated with an 
increased risk of breast cancer recurrence. 
 
In study I, disease-free, overall and breast cancer-specific survival were worse for women 
undergoing conventional mastectomy without implant-based IBR, even though the difference 
did not reach statistical significance. In studies II-III, however, this phenomenon was stronger, 
especially regarding overall survival. A systematic review and meta-analysis by De la Cruz et 
al included 20 studies investigating DFS and OS in NSM, a majority of which showed superior 
survival in the NSM groups when compared with patients undergoing conventional 
mastectomy or SSM155. Likewise, a number of studies suggest superior survival in delayed 
autologous flap reconstruction200,202. A majority of previous studies are in line with our results 
concluding that DIEP flap reconstruction is not associated with worse survival. Importantly, it 
would be inaccurate to conclude that an IBR or delayed autologous flap reconstruction such as 
DIEP would actually improve breast cancer survival. Instead, these findings should suggest 
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selection mechanisms and thus potential differences between the reconstructed and the control 
groups which were unaccounted for in analyses. 
 
Smokers and patients with a high BMI (>30) are normally not admitted to receive implant-
based IBR or delayed DIEP flap reconstruction since these are known risk factors for adverse 
surgical outcomes such as infection, wound dehiscence and reconstructive failure. Therefore, 
a higher prevalence of these factors, also increasing the risk of recurrence and survival, may 
have been present in the control groups. In studies I-III, data on these factors were incomplete 
and could unfortunately not be investigated. Stage at diagnosis, treatment, comorbidity and 
SES further affect who is offered breast reconstruction261,263,336. SES affects the access to breast 
reconstruction whilst comorbidities greatly influence the selection of patients for 
reconstruction102,261,263,269,270,337,338. More importantly still, all these factors are intricately 
associated with each other and with survival outcomes (see Figure 11).  
 
Thus, the presence of confounding factors not registered in the original database, such as 
differences in SES and comorbidity, could well be an explanation for the different recurrence 
rates in study I, and at the same time constitute major selection criteria for reconstruction: 
Women employed outside of home and those with a higher education, for example, have a 
higher probability to undergo IBR than unemployed and retired patients263,339. The sensitivity 
analysis in study III substantiated the hypothesis that patients undergoing NSM with IBR 
represent a selected group of patients with lower comorbidity and a higher SES.  
 
The complexity of study III lies in that both lower SES and significant co-morbidities are 
confounding factors for tumour stage at breast cancer diagnosis as well as for treatment, thus 
acting as a possible competing cause of death. These factors will therefore affect OS but also 
BCSS by modulating adjuvant treatments such as chemotherapy and radiotherapy, both of 
which influence survival251,263,340. The persistence of a survival difference between the DIEP 
flap and control group after adjustments in study III suggests either the presence of hitherto 
unmeasured confounders or a cumulative effect of multiple covariates that may interact in a 
complex and synergistic ways. 
 
Even though comorbidity was adjusted for in study III, the CCI score does not include 
psychiatric disorders, alcohol and drug abuse, immunosuppressive therapy, bleeding disorders 
or major surgery, and could thus be too blunt to detect subtler differences between the groups. 
It could therefore be that a DIEP flap reconstruction is a proxy for better general health, 
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including comorbidity but also a lower BMI and no smoking habits, which in turn is closely 





Figure 11. Causal diagram, i.e a directed acyclic graph (DAG) illustrating the interrelations of 
socioeconomic factors, comorbidity, tumour stage and treatment modalities with the exposures nipple-
sparing mastectomy (NSM) with implant-based immediate breast reconstruction (IBR) and deep 
inferior epigastric perforator (DIEP) flap breast reconstruction and the outcome breast cancer death. 
Green boxes represent exposures, blue boxes represents the outcome or the mediators of outcome and 
red boxes represent confounding factors. Green arrows represent causal paths and red arrows represent 
biasing paths. Created through DAGitty v3.0. 
 
 
In conclusion, this thesis shows that both NSM with implant-based IBR and delayed DIEP 
reconstruction can be considered oncological safe procedures with no adverse effect on cancer-
specific outcome. Patients opting for breast reconstruction represent a more privileged subset 
of women in terms of SES and comorbidity; still, differences in OS persisted after adjustment 
for these factors, most possibly due to selection mechanisms. Although the oncological safety 
of these procedures is thus suggested, there are other adverse effects to consider in the 





5.2 RADIOTHERAPY AND BREAST RECONSTRUCTION  
Women in the prior RT group in study IV had the highest incidence of IBR failure and reported 
the lowest scores on four out of five BREAST-Q subscales. Previous studies have reported 
results in line with our findings, suggesting that prior RT is an independent risk factor for IBR 
failure regardless of surgical technique341 and that women with prior RT have a significantly 
lower quality of life than those receiving postoperative RT or those without any RT342. It is 
important to consider the reasons for prior RT: a majority of such patients have undergone 
previous breast surgery for breast cancer, and thus undergo their mastectomy due to breast 
cancer recurrence. This increases surgical risks, but also points at a different severity of the 
disease and should be suspected to have a negative influence on BREAST-Q scores.  
 
Long-term consequences of breast reconstruction on physical and psychosocial well-being are 
essential to investigate in order to take the patients’ perspective into account. Although RT is 
associated with adverse effects, a study investigating patients undergoing bilateral implant 
reconstruction with unilateral irradiation did not show any significant differences in patient 
satisfaction despite higher complication rates in the irradiated breast343. A study by our group 
showed higher rates for IBR failure in patients with RT, but also that a majority of those without 
failure would again choose to undergo reconstruction and encourage other patients to do so175. 
Some authors state that the adverse effects of radiotherapy should be met with autologous 
breast reconstruction and that patients undergoing autologous reconstruction generally report 
higher cosmetic satisfaction when compared with implant-based reconstruction167,300. It is often 
argued that satisfaction with IBR deteriorates over time, but our results could not support that. 
It is, however, important to consider that IBR failure is more common in irradiated patients, 
and a larger proportion of irradiated than unirradiated patients was therefore lost in PRO 
analyses. Consequently, women suffering IBR failure or choosing to convert to autologous 
breast reconstructions are those likely to experience declining satisfaction over time, leaving 
only the most satisfied women in the PRO analysis. In conclusion, although the adverse effects 
of RT on IBR were again confirmed, the satisfaction of those patients who do not suffer IBR 
failure or choose to convert to autologous reconstruction does not deteriorate over a long 







5.3 STRENGTHS AND LIMITATIONS  
One of the main strengths of studies I-III is the population-based matched cohort design, 
reducing the confounding of non-randomized investigations and providing a relatively high 
level of evidence. The strict matching procedure adjusted for patient and tumor characteristics, 
aiming at gaining as much similarity to a randomized control trial as possible, since a 
randomized design would not be ethically feasible in a reconstructive setting today.  
Study I is to our knowledge the first matched cohort study comparing NSM and IBR with 
conventional mastectomy, providing evidence that NSM can be considered an oncological safe 
procedure in selected cases with a negative retroareolar biopsy. However, the study included a 
limited study group, and follow-up time was rather short, making firm conclusions hard to 
draw. 
 
In studies I-II, the matching procedure can be regarded as successful since the matching 
criteria did not differ between both groups. All studies were based on data collected from well-
maintained registers, and all patients underwent surgery in Stockholm, hence eliminating 
geographical variations in selection criteria and even standards of treatment. Furthermore, data 
on tumour characteristics, treatment, recurrence and death were verified by individual review 
of medical charts for all studies included in this thesis.   
 
In study III, the matching procedure did not account for patients undergoing IBR since the 
matching was primarily designed for study II where IBR was expected not to affect survival 
in accordance with published evidence. Another limitation in studies II-III is the low coverage 
of important confounding factors such as BMI and smoking habits in the control group. With 
consideration of the retrospective nature of the study, this missingness could not be adjusted 
for, and these variables could therefore not be further analysed.  
 
One main strength of study IV is the long follow-up time, allowing for a long-term evaluation 
of both IBR failure and PROs.  Detailed clinical data were obtained from medical charts leading 
to low missingness on tumour characteristics and detailed data on IBR failure, complications 
and reoperations.  One of the main limitations in study IV is that patients with IBR failure 
could not report PROs since the BREAST-Q modules used in this study is impossible to be 
completed by women who have converted their implant reconstruction to an autologous 




5.4 METHODOLOGICAL CONSIDERATIONS 
5.4.1 Biases  
5.4.1.1 Indication bias 
Indication bias, or confounding by indication, defines a covariate caused by the indication for 
the exposure but also known to affect the outcome (i.e. smoking, comorbidity, BMI), thereby 
modifying an association between the exposure and the outcome. Indication bias is a crucial 
factor in the setting of studies II-III as patients receiving a delayed DIEP flap reconstruction 
represent a specific subset of breast cancer patients, confounded by indication of the procedure.  
As a majority of breast cancer recurrences are most likely to occur within the first two years 
after index surgery79,192,207, patients at Karolinska University hospital commonly receive a 
DIEP flap reconstruction earliest 24 months after mastectomy. This creates a ‘security margin’ 
between mastectomy and DIEP flap reconstruction which we tried to compensate for by only 
allowing controls without any recurrence during the corresponding time interval. The 
metastasis screening undertaken in all patients undergoing DIEP flap reconstruction, however, 
could further have biased the survival analysis, since the control group may have included 
patients whose recurrence would have been detected by such screening but was thus left 
undetected at the time of study inclusion. This may have contributed to the superior survival 
outcomes after DIEP flap reconstruction. 
 
5.4.1.2 Selection bias  
Selection bias implies that study participants may differ systematically from the population of 
interest. For example, patients included in the NSM or DIEP groups may be healthier, more 
well-informed, and more often non-smokers with a lower BMI than the general population, 
thereby not representing all breast cancer patients. Selection bias can arise because groups of 
participants may be different in other ways than the exposure, leading to the results being biased 
by confounding.  
 
Since the aim of studies I-III was to study the reconstructive groups specifically, no inferences 
were drawn on the overall population of breast cancer patients but control groups of patients 
undergoing conventional mastectomy were used for comparison. Interestingly, a subset of 
patients in the control group as well as in the DIEP group had also undergone IBR in study II-
III, which, if anything, would have mitigated the observed effects since IBR patients were 
found to be as selected a group as DIEP patients.  
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One potential selection bias in study IV is that patients choosing to respond to both BREAST-
Q questionnaires (i.e. 2012 and 2020) are patients satisfied with the reconstructive results, and 
that the most dissatisfied patients had either undergone implant removal or autologous 
reconstruction, or declined to participate in the second survey, thereby filtering out the least 
satisfied cases. Recall bias, i.e. systematic error due to lack of completeness or accuracy to 
recall past events or experiences, for example HRQoL at the time of IBR, was limited in this 
study as the main focus was to investigate the patient-reported outcomes at the moment when 
the questionnaire was being filled out. Since follow-up times were similar in all groups, and 
varied within groups, recall bias should be equally affecting all studied groups. 
 
5.4.1.3 Immortal time bias  
“Immortal time” refers to the time during follow-up time in which the study participants cannot 
experience the outcome at question. In studies II-III, the follow-up time was calculated both 
from the time of primary mastectomy as well as from the date of DIEP flap reconstruction or 
the assigned corresponding time point in control patients. Only the timescale including date of 
DIEP or index date was, however, included in the survival analysis in order to minimize the 
risk of immortal time bias.   
 
Because the DIEP group was required to be alive and event-free between mastectomy and the 
DIEP flap reconstruction, they are during this time considered “immortal” and contributed to 
“immortal time” to the DIEP group by design. If misclassified or excluded only in the exposure 
group, the immortal time could lead to biased associations conferring to advantages in survival 
to the DIEP group. The control group, however, fulfilled the same requirements of 
“immortality” during the matched time interval.  
 
5.4.1.4 Non-response bias 
Non-responder bias occurs due to meaningful differences between responders and non-
responders. This bias has been described to convey serious concern in survey studies as it may 
implicate that patient not responding may differ from those who do, both in aspects of exposure 
and outcome. If unaccounted for, this could lead to mistakenly estimating population 
characteristics based on the underrepresentation of some aspects due to non-response. Since 
previous questionnaire-based studies have reported lower response rates in groups with lower 
SES 344, a non-responder analysis was undertaken in study IV. This confirmed that the no 
significant differences were seen between the groups, thereby reducing the non-response bias. 
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5.4.1.5 Lead-time bias  
Lead time is the period between the detection of a disease and its clinical manifestation, which 
may be affected by e.g. mammography screening. Lead-time bias hence refers to the 
phenomenon where the early detection of a disease falsely implicates longer survival periods. 
This attribute is frequently discussed in the context of screening, but also in the context of 
socioeconomic factors affecting time of diagnosis.  
 
In our studies, the modality of breast cancer detection was not taken into account, but instead, 
tumour stage was matched for (studies I-III). All patients included in studies I-III were 
citizens of Stockholm, where attendance at mammography screening is high345.  Differences in 
survival rates between the groups should thus not be due to lead-time bias attributed to 
differences in attendance to mammography screening. In all studies, the median patient age 
was within the mammography screening age range. Nevertheless, high screening attendance is 
more common to patients of higher SES and lower comorbidity, leading to potential differences 
in detection rate based on these differences. 
 
  
5.4.2 Internal and external validity  
In order to draw valid conclusions for an entire population based on a study sample, it is crucial 
to assess internal and external validity. Internal validity refers to that conclusion are valid and 
free from biases for the study sample only, whereas external validity regards validity for the 
entire population from which the sample is drawn. External validity hence refers to the 
generalizability of the study sample to the entire clinical population. Internal validity can be 
affected by either random or systematic errors such as confounding, selection bias or 
measurement error. While systematic errors are not affected by sample size, random error 
decreases with larger sample sizes, leading to narrower confidence intervals and hence more 
precise estimates. In order to obtain both precise and valid estimates, systematic errors need to 
be accounted for.  
 
For this thesis, information was obtained from nationwide registers with high coverage and 
validity, and all patients were operated at either the same hospital (Karolinska University 
Hospital, studies I-III) or within the same region. These factors increase the internal validity 
and with the adjustment for confounding factors, the chance of external validity was increased. 
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6 ETHICAL CONSIDERATIONS 
In our research group, discussions regarding ethical concerns are constantly alive. Prior to 
every planned study, pros and cons will be weighed against each other and further analyzed for 
possible harm versus benefit for included patients. This research project is of substantial 
significance in the field and may contribute valuable information to the ongoing debate 
concerning the oncological safety following immediate and delayed breast reconstruction. It is 
therefore of clinical importance that the studies were conducted.   
All studies were approved by the Ethics Committee at Karolinska Institutet in Stockholm. 
Some data were requested from the Regional Cancer Centre (RCC), Statistics Sweden and The 
National Board of Health and Welfare, while others were obtained by reviewing patients’ 
medical records. These data are sensitive data including information on health, socioeconomic 
index, educational and occupational level along with individual and household disposable 
income. Data were therefore de-identified by Statistics Sweden and The National Board of 
Health and Welfare before delivery.  
 The use of questionnaires in order to investigate patient-reported outcomes might be 
uncomfortable for some patients since this might bring back feelings of anxiety associated with 
the own breast cancer diagnosis. A letter was included with the survey explaining the project 
and underlining the fact that participation is voluntary. It was carefully assured that the survey 
was only sent out to patients still alive in order to not upset remaining family members. Ethical 
dilemmas in this study could include that the personal information extracted from medical 
charts is obtained without the patient individually consenting to this procedure, which can be 
seen as a violation of personal integrity. Therefore, the chiefs of departments at all involved 
hospitals signed a certificate on behalf of their patients, allowing researchers to review medical 
records. The presentation of the results includes information on an anonymous group level and 
statistical findings, making personal identification of individuals impossible. After thorough 
analysis, we conclude that the clinical advantage obtained from the results of the undergone 









I. Nipple-sparing mastectomy in the context of immediate implant-based breast 
reconstruction in selected breast cancer patients does not negatively impact on 
oncological safety. 
 
II. Delayed DIEP flap reconstruction does not increase the risk of breast cancer recurrence 
or death. 
 
III. Women with a delayed DIEP flap reconstruction belong to a selected group of higher 
socioeconomic status and better health than women undergoing mastectomy without 
any delayed reconstruction, which could explain higher survival estimates in DIEP 
patients. 
 
IV. Prior and postoperative irradiation increases the risk of reconstructive failure and 
negatively affects patient-reported outcomes, but effects over time are moderate. 
Previously irradiated patients should be strongly recommended to consider autologous 
reconstruction instead of implant-based options.   
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8 FUTURE ASPECTS 
While this thesis sheds light on some important research questions regarding the safety of two 
common reconstructive methods, many more questions remain unanswered, some of which are 
outlined below. 
 
Patient satisfaction and quality of life are gaining increasing attention, and by involving patients 
in the decision-making process leading up to a reconstruction, a higher patient satisfaction 
should be achievable. Since our data stem from retrospective data collection and thus gather 
PROs at non-standardized time points, it would be of interest to prospectively register data on 
breast cancer patients specifically looking at long-term complications, satisfaction and quality 
of life after breast reconstruction. Since the BREAST-Q questionnaire is not applicable for 
patients suffering reconstructive failure, such data collection should include further 
questionnaires not depending on the reconstructive outcome. Such a prospective PRO 
registration is now underway by a nationwide initiative of the Regional Cancer Centers. 
 
One important subject for future research associated with studies I and II is the potential 
influence of postoperative complications on oncological outcomes. Breast cancer reactivation 
may be initiated through new mutations and scattering of secondary micrometastases, but also 
through increased levels of growth factors as seen in postoperative complications. Breast 
reconstruction is associated with a higher risk of postoperative complications than conventional 
mastectomy, and an important issue to investigate is therefore whether postoperative 
complications increase the risk of recurrence in patients undergoing implant-based IBR or 
DIEP reconstruction.  
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9 SAMMANFATTNING PÅ SVENSKA 
I samband med bröstcancerkirurgi kan bröstrekonstruktion genomföras antingen i samma 
seans, så kallad omedelbar eller primär rekonstruktion (immediate breast reconstruction, IBR) 
eller i en andra seans, så kallad sen eller sekundär rekonstruktion. Målsättningen med denna 
avhandling var att studera den onkologiska säkerheten för en allt vanligare metod av implantat-
baserad IBR där bröstvårta samt vårtgård sparas (mamill-sparande mastektomi eller nipple-
sparing mastectomy, NSM) respektive sekundär rekonstruktion med kroppsegen hud och 
fettvävnad från buken, så kallad Deep Inferior Epigastric Perforator (DIEP) lambå. Vidare 
ämnade vi studera skillnader i socioekonomi och samsjuklighet bland patienter som genomgår 
en DIEP rekonstruktion jämfört med en matchad kontrollgrupp. Slutligen var en av 
målsättningarna att studera de långsiktiga effekterna av strålning på implantat-baserad IBR 
genom att undersöka riskfaktorer till protesförlust, samt att evaluera patientrapporterade 
utfallsmått. 
I studie I inkluderades samtliga kvinnor som genomgått NSM på Karolinska 
Universitetssjukhuset 2000-2012. Gruppen matchades till en kontrollgrupp bestående av 
bröstcancerpatienter som hade genomgått mastektomi utan efterföljande primär 
rekonstruktion. Totalt inkluderades 69 fall och 206 kontroller. Inga lokalrecidiv registrerades i 
studiegruppen jämfört med sju stycken i kontrollgruppen (P=0.197), och inga signifikanta 
skillnader i överlevnad kunde identifieras.  
I studie II-III inkluderades samtliga patienter som hade genomgått en sekundär rekonstruktion 
med DIEP lambå vid Karolinska Universitetssjukhuset 1999-2013 (254 DIEP fall) samt en 
kontrollgrupp av bröstcancerpatienter som hade genomgått mastektomi utan sekundär 
rekonstruktion (729 kontroller). I studie II ämnade vi att studera risken för bröstcancerrecidiv 
samt bröstcancer-specifik överlevnad (BCSS). Bröstcancerrecidiv var vanligare i 
kontrollgruppen (23.9 %) än i DIEP-gruppen (19.7 %, P=0.171). Efter justering för 
tumörfaktorer samt behandling var den totala femårs-överlevnaden (HR 1.91, 95 % CI 1.22–
2.98), men inte den bröstcancer-specifika (HR 1.35, 95 % CI 0.80-2.26), signifikant lägre i 
kontrollgruppen än i DIEP-gruppen. I studie III ämnade vi att undersöka huruvida dessa 
överlevnadsskillnader påverkats av socioekonomiska faktorer och samsjuklighet. I gruppen 
som genomgick DIEP rekonstruktion var det oftare förekommande att fortsätta utbildningen 
efter grundskolan, att ha en högre inkomst och att befinna sig i en relation, samt att ha en lägre 
samsjuklighet enligt Charlson Comorbidity Index. Efter justering för dessa faktorer var den 




I studie IV inkluderades samtliga bröstcancerpatienter som genomgått implantat-baserad IBR 
vid något av de fyra Stockholmssjukhusen 2007-2011 (754 fall). Dessa hade redan undersökts 
2012 med enkäten BREAST-Q, som studerar fysiskt och psykiskt välmående samt nöjdhet med 
rekonstruktionen. Kohorten delades in i tre strålbehandlingsgrupper: 386 fall som inte erhållit 
strålbehandling (radiotherapy, RT), 64 som hade erhållit RT innan IBR samt 304 fall som 
erhållit RT efter IBR. Primärt utfallsmått var implantatförlust, definierat som borttagning av 
protes med eller utan samtidig eller senare bröstrekonstruktion med kroppsegen vävnad. Totalt 
128 fall (17 %) av protesförlust registrerades: 8.8 % i den icke strålade gruppen, 31.3 % i den 
tidigare strålade gruppen och 24.3 % i gruppen som erhållit postoperativ RT. Riskfaktorer för 
implantatförlust var RT, ålder >50 år vid tidpunkten för IBR, BMI > 25, och postoperativa 
kirurgiska komplikationer. 
 BREAST-Q enkäten skickades till samtliga patienter i livet som inte nått det primära 
utfallsmåttet. Svarsfrekvensen var 72.2 %. Kvinnor som tidigare erhållit RT skattade lägst i 
jämförelse med de andra två grupperna på de flesta skalor av enkäten. Kvinnor som erhållit 
postoperativ RT skattade signifikant lägre endast på skalan för fysiskt välmående. 
Longitudinella jämförelser mellan undersökningen år 2012 och 2020 visade att skattningarna 
på skalan för psykosocialt välmående hade ökat bland kvinnorna som erhållit postoperativ RT. 
De icke strålade kvinnorna rapporterade lägre nöjdhet än tidigare avseende brösten samt 
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